



1

DRAFT

2

3

4

EXPERT PANEL ON EFFECTIVE WAYS OF INVESTING IN HEALTH

5

6

(EXPH)

7

8

9

10

11

12

Opinion on Benchmarking Access to Healthcare in the EU

13

14

15

16

17

18

19

20

21

22

23

24

25

26

27

28

29

30

31

32

The EXPH adopted this opinion at the xx^h plenary of xx

About the EXPert Panel on effective ways of investing in Health (EXPH)

Sound and timely scientific advice is an essential requirement for the Commission to pursue modern, responsive and sustainable health systems. To this end, the Commission has set up a multidisciplinary and independent Expert Panel which provides advice on Effective Ways of Investing in Health (Commission Decision 2012/C 198/06).

The core element of the Expert Panel's mission is to provide the Commission with sound and independent advice in the form of opinions in response to questions (mandates) submitted by the Commission on matters related to health care modernisation, responsiveness, and sustainability. The advice does not bind the Commission.

The areas of competence of the Expert Panel include, and are not limited to, primary care, hospital care, pharmaceuticals, research and development, prevention and promotion, links with the social protection sector, cross-border issues, system financing, information systems and patient registers, health inequalities, etc.

Expert Panel members

Christian Anastasy, Pedro Barros, Margaret Barry, Aleš Bourek, Werner Brouwer, Jan De Maeseneer (Chair), Dionne Kringos, Lasse Lehtonen, Martin McKee, Liubove Murauskiene, Sabina Nuti, Walter Ricciardi, Luigi Siciliani and Claudia Wild

Contact:

European Commission
DG Health & Consumers
Directorate D: Health Products and Systems
Unit D3 – eHealth and Health Technology Assessment
Office: B232 B-1049 Brussels

SANCO-EXPERT-PANEL@ec.europa.eu

66 ACKNOWLEDGMENTS

67
68 Members of the Working Group are acknowledged for their valuable contribution to this
69 opinion.

70
71
72 The members of the Working Group are:

73 Expert Panel members

74
75 Chair: S Nuti

76 Rapporteur: M. McKee

77 L. Lehtonen

78 M. Barry

79 L. Siciliani

80 L. Murauskiene

81 A. Bourek

82 C. Anastasy

83 D. Kringos

84 J. De Maeseneer

85 P. Pita Barros

86 W. Brouwer

87
88
89
90 The declarations of the Working Group members are available at:
91 https://ec.europa.eu/health/expert_panel/experts/members_en

92
93 We are grateful to Marina Karanikolos for assistance with data analysis.

94

95 Summary

96
97 Faced with growing evidence that some groups within European Union Member States
98 have been unable to achieve access to necessary healthcare, the European Union has
99 committed to action to reduce levels of unmet need, most recently as an element of the
100 European Pillar of Social Rights. In response, the Expert Panel on Effective Ways of
101 Investing in Health has been requested to propose a series of quantitative and
102 qualitative benchmarks for assessing progress in reducing unmet need for healthcare
103 and to discuss means by which EU funds or other mechanisms might be used to improve
104 access to healthcare.

105 A first step is to define need for healthcare. This is the ability to benefit from it, meaning
106 that the individual in question has a condition that causes him or her to be in less than
107 good health but also that there is a treatment available that can improve their health,
108 whether curative, life-sustaining or enhancing, or merely palliative. While recognising
109 that there may be clinical reasons, such as low levels of cost effectiveness, for denying
110 treatment in the face of limited resources, treatment should never be withheld on moral
111 grounds.

112 In practice, however, there are many challenges involved in measuring unmet need for
113 particular interventions, precluding its routine use. Consequently, a pragmatic solution
114 involves the use of survey data in which individuals are asked whether they have
115 experienced a need for healthcare but were unable to obtain that care. These data are
116 collected throughout the European Union annually in the Survey of Income and Living
117 Conditions (EU-SILC), with subsidiary questions that ask about the reasons for unmet
118 need. The report of the Panel recognises that this approach has a number of limitations,
119 and also that there are other sources of data that provide insights into the extent to
120 which you need for healthcare is being met, including comparative data on outcomes
121 related to healthcare, but for the present, the EU-SILC data are the only timely and
122 comparable source of information available across all Member States.

123 Using this measure, the Panel draws attention to persisting evidence of relatively high
124 rates of unmet need in some Member States, and some groups within them.

125 The Panel notes that, consistent with the political objective of achieving convergence
126 within the European Union, there is a strong argument for setting a target for unmet
127 need that is close to that already achieved by the most privileged group within the best
128 performing Member State. However, given the very differing starting positions, the Panel
129 considers that this is, for the present time, unrealistic. It is beyond the scope of the
130 Panel to propose a precise target for reduction in unmet need, given that this will require
131 the commitment of financial and other resources. Instead, the Panel has proposed a
132 mechanism for setting such a target. This involves setting a benchmark of the median
133 value achieved by the best performing Member States, with the expectation that those
134 Member States not yet achieving it should narrow the gap by a given percentage, which
135 might be around 50%, over a defined period of time, which might be three years. Such a
136 target would be ambitious, requiring a significantly faster rate of reduction and has been
137 achieved in recent years in many Member States but, in our view, would be achievable.

138 The Panel was also asked to identify second level indicators. Taking a pragmatic
139 approach, based on the availability of data, it proposes that this should follow the
140 questions that are included in the EU-SILC data. These provide information on
141 affordability, availability, and acceptability of health services. The Panel did, however,
142 note the importance of developing additional sources of data that can be collected
143 regularly to provide more detailed insights into the levels, patterns, and determinants of
144 unmet need for healthcare across the European Union.

145 The Panel was requested to identify qualitative measures of unmet need. This is
146 particularly challenging, given the many and diverse reasons for unmet need for

Benchmarking Access to Healthcare in the EU

147 healthcare, both among and within Member States. The Panel was not convinced that a
148 standard reporting system was appropriate. Rather, it was recommended that each
149 Member State identify those groups that are most likely to be disadvantaged, according
150 to factors such as age, gender, education, ethnicity, or employment status, analyse the
151 appropriate data, and prepare a report on the level and pattern of unmet need among
152 disadvantaged groups, accompanied by recommendations for action. The Panel also note
153 the value of shadow reports produced by civil society organisations in other areas and
154 encourages the production of such reports.

155 Finally, the Panel reviews the scope for using European Union funds to improve access to
156 healthcare. It notes that, as the problems facing each Member State differ, as well as
157 the extent to which each of them is eligible for different forms of support. However, it
158 notes that there are many opportunities for using vehicles such as Structural Funds,
159 research funds, and European Reference Networks.

160

161

162 Opinion to be cited as :

163 EXPH (EXpert Panel on effective ways of investing in Health).Opinion on Benchmarking
164 Access to Healthcare in the EU. Brussels: European Commission, 2017.

165

166

167 The opinions of the Expert Panel present the views of the independent scientists who are
168 members of the Expert Panel. They do not necessarily reflect the views of the European
169 Commission. The opinions are published by the European Union in their original language
170 only.

171 http://ec.europa.eu/health/expert_panel/index_en.htm

172

173 Contents

174	Summary.....	4
175	Table of figures	7
176	Table of tables	7
177	Table of boxes.....	7
178	1. BACKGROUND.....	8
179	2. TERMS OF REFERENCE	10
180	3. OPINION	11
181	3.1. Context.....	11
182	3.2. Why was this opinion requested?	14
183	3.3. Defining need	15
184	3.4. How is unmet need measured at a European level?	20
185	3.5. Trends in unmet need in Europe	25
186	3.6. Reasons for unmet need	30
187	3.7. Proposal for an overall target	31
188	3.8. Proposal for national targets	31
189	3.9. Inequalities within Member States.....	35
190	3.10. Second level indicators	36
191	3.10.1. Affordability.....	38
192	3.10.2. Availability & Accessibility	43
193	3.10.3. User experience	45
194	3.10.4. Inequalities & Inequities.....	48
195	3.11. Proposals for additional data collection	52
196	3.12. Policies to reduce unmet need	53
197	3.12.1. Affordability.....	53
198	3.12.2. Availability & Accessibility	54
199	3.12.3. User experience	55
200	3.13. Scope for action	55
201	3.14. Proposals for qualitative measures	60
202	3.15. Scope for utilization of EU funds and/or other mechanisms to support the	
203	improvement of access to healthcare according to the benchmarks proposed.	65
204	3.16. Conclusion.....	68
205	4. LIST OF ABBREVIATIONS.....	70
206	5. REFERENCES.....	71
207		
208		

Benchmarking Access to Healthcare in the EU

209 **Table of figures**

210	
211	Figure 3-1 Variation in rates of musculoskeletal MRIs among those aged 65 or above
212	in regions in the Italian Regional Collaborative, 2015 17
213	Figure 3-2 Percentage reporting unmet need for health care in Member States 2015 . 25
214	Figure 3-3 Share of people reporting unmet need for health care due to cost, travel
215	distance, and waiting list by income, age, gender, education and employment status, EU
216	28, 2005-2015 26
217	Figure 3-4 Unmet need and % of people reporting poor health, 2015..... 27
218	Figure 3-5 Unmet need and total mortality per 100,000 (2014)..... 28
219	Figure 3-6 Unmet need and GDP per capita, 2013 29
220	Figure 3-7 Unmet need and Total Health Expenditure (PPS, 2014)..... 29
221	Figure 3-8 Gap between level of unmet need in 2015 and benchmark based on best
222	performance in past three years..... 35
223	Figure 3-9 Out-of-pocket expenditure as a share of final household consumption.... 40
224	Figure 3-10 Out-of-pocket expenditure as a share of total health expenditure..... 41
225	Figure 3-11 Unmet need for health care due to unaffordability 43
226	Figure 3-12 Median waiting time (from specialist assessment to treatment) for hip
227	replacement 48
228	Figure 3-13 Percentage of respondents reporting unmet need due to care being too
229	expensive, too far to travel, or long waiting list, by income quintile (2015)..... 51
230	

231 **Table of tables**

232	Table 3-1 Health Access and Quality Index scores for EU Member States, 2015 24
233	

234 **Table of boxes**

235	Box 3-1 Questions on unmet need in EU-SILC (UK questionnaire) 21
236	Box 3-2 Challenges in interpreting the EU-SILC question on unmet need..... 22
237	Box 3-3 Possible formula for generating target for unmet need..... 34
238	Box 3-4 Waiting times for non-emergency treatments across the EU 47
239	Box 3-5 Checklist for measures to address unmet need 64

240

241

242 **1. BACKGROUND**

243 During the economic turbulence of recent years, it has become clear that some groups
244 within society have been unable to obtain the healthcare they require. Longstanding
245 barriers to access have been exacerbated by the financial crisis, stimulating an active
246 debate in many parts of Europe about how to respond.

247 In 2015 the five Presidents' report set out a new direction for Europe, including a
248 stronger focus on social performance (Juncker, Tusk et al. 2015). They made clear that
249 Europe's ambition should be to earn what was termed a 'social triple A'. The current
250 Commission has taken a series of actions on access to good-quality healthcare; the
251 following are three of the most relevant examples:

- 252 • In the European Semester the Annual Growth Surveys, which set out the EU
253 priorities to boost growth and job creation for the coming year, have increasingly
254 acknowledged the importance of access to healthcare. This has given it greater
255 importance and visibility in the European Semester process and in the resulting
256 recommendations to Member States and has been accompanied by growing interest
257 in inequalities more generally, but especially in health.
- 258 • The Expert Group on Health System Performance Assessment promotes discussions
259 between EU Member States and international organizations on methodologies and
260 tools to assess the performance of health systems; it has recently published a report
261 on quality of healthcare (OECD 2016) and is expected to focus attention on access to
262 care over the next year.
- 263 • The Expert Panel on Effective Ways of Investing in Health, in its opinion on access to
264 health services of 2016, showed that rates of unmet need for health care was an
265 increasing problem in the EU and set out options for how to maximise the added
266 value of EU action on access to healthcare (Expert Panel on effective ways of
267 investing in Health 2016).
- 268 • On 26 April 2017 the Commission presented in its Communication and
269 Recommendation the European Pillar of Social Rights. It aims to serve as a compass

Benchmarking Access to Healthcare in the EU

270 for a renewed process of both economic and social convergence, towards better living
271 and working conditions. The Commission tabled also the proposal for an
272 Interinstitutional Proclamation of the European Pillar of Social Rights to be adopted
273 by the Commission, the Council, and the Parliament, which is expected to be adopted
274 by the end of 2017.

- 275 • The principles and rights enshrined in the Pillar are structured around three
276 categories: equal opportunities and access to the labour market, fair working
277 conditions and social protection and inclusion. They focus on how to tackle new
278 developments in the world of work and society at large so as to deliver on the
279 promise of the Treaties of a highly competitive social market economy, aiming at full
280 employment and social progress. One of 20 principles of the Pillar is that everyone
281 has the right to timely access affordable, preventative and curative care of good
282 quality.
- 283 • The European Pillar of Social Rights is accompanied by a 'social scoreboard' which will
284 monitor the implementation of the Pillar by tracking trends and performances across
285 EU countries in 12 areas - one of which is healthcare (unmet need for medical care) -
286 and will feed into the European Semester of economic policy coordination. The
287 scoreboard will also serve to assess progress towards a social 'triple A' for the EU as
288 a whole.

289

290

291 **2. TERMS OF REFERENCE**

292 The Expert Panel on effective ways of investing in Health is requested to provide its
293 views on Benchmarking Access to Healthcare by:

- 294 1. Proposing a quantitative benchmark/target on access to healthcare based on an
295 indicator of unmet need for medical care. A target for the EU and a target which
296 can be adapted to the context of each Member State should be proposed.
- 297 2. Proposing a qualitative benchmark, based on principles and policy levers that can
298 be operationalised, to improve access to healthcare in the EU Member States.
- 299 3. Discussing the possible utilization of EU funds and/or other mechanisms to support
300 the improvement of access to healthcare according to the benchmarks proposed.

301

302 **3. OPINION**

303 **3.1. Context**

304 Although health, and especially health care, initially had only a limited presence in the
305 European Treaties (McKee, Mossialos et al. 1996), this has expanded considerably over
306 time, including, in the past decade, growing attention to access to health care (Greer,
307 Hervey et al. 2013). In parallel, there have been a series of developments in the wider
308 international arena, and particularly within the framework of the United Nations, in which
309 Member States have stated their commitment to the right to health and access to care
310 (Sridhar, McKee et al. 2015).

311 Within the European Union, the Council of Ministers agreed a set of common values and
312 principles for EU health systems in 2006. One of these was access to good quality care.
313 This right was subsequently enshrined in the Charter of Fundamental Rights (Article 35),
314 which provided all EU citizens with a legal “right of access to preventive health care and
315 the right to benefit from medical treatment under the conditions established by national
316 laws and practices”.

317 In 2017, the European Commission set out proposals for a European Pillar of Social
318 Rights (European Commission 2017). Containing 20 principles, this is intended to build
319 on, and complement, the EU social “acquis”, guiding policies in a number of fields
320 essential for well-functioning and fair labour markets and welfare systems within the
321 participating Member States. The principles proposed do not replace existing rights, but
322 offer a way to assess and, in future, more closely align the performance of national
323 employment and social policies. These proposals will be discussed at a European Social
324 Summit, to be held in Stockholm in November 2017. Once established, the Pillar should
325 become the reference framework to screen the employment and social performance of
326 participating Member States, to drive the process of reforms at national level and, more
327 specifically, to serve as a compass for renewed convergence within the euro area.
328 Principle 16 states that “Everyone has the right to timely access to affordable, preventive
329 and curative health care of good quality”, although this is a dilution of what was in an

Benchmarking Access to Healthcare in the EU

330 earlier draft, which included the words “and the need for healthcare shall not lead to
331 poverty or financial strain”.

332 Finally, although the arrangements for providing health care are reserved to Member
333 States by the Treaties, the European Union can play a role by facilitating the exchange of
334 information. In pursuit of this goal, it has convened an Expert Group on Health System
335 Performance Assessment, working with OECD, which is likely, in the near future, to pay
336 particular attention to access to health care.

337 The rationale for including this right in the Charter reflects several considerations. The
338 first is that all Member States have committed, within the United Nations system, to the
339 progressive realisation of the right to health, as set out in the International Covenant on
340 Economic, Social, and Cultural Rights (United Nations 1966). The Committee on
341 Economic, Social, and Cultural Rights, the body charged with monitoring the Covenant,
342 has subsequently interpreted this as creating a set of core principles, as follows:

343 *All states, no matter how poor, should offer a minimum core level of provision, which*
344 *should include at least the following obligations:*

- 345 • *To ensure the right of access to health facilities, goods and services on a non-*
346 *discriminatory basis, especially for vulnerable or marginalised groups*
- 347 • *To provide essential drugs, as from time to time defined under the [World Health*
348 *Organization] Action Programme on Essential Drugs*
- 349 • *To ensure equitable distribution of all health facilities, goods and services [based on*
350 *need]*
- 351 • *To adopt and implement a national public health strategy and plan of action, on the*
352 *basis of epidemiological evidence, addressing the health concerns of the whole*
353 *population*

354 These principles have subsequently been incorporated into the Sustainable Development
355 Goals, which once again, all Member States have committed to. Specifically, Goal 3.8
356 commits Member States to “Achieve universal health coverage, including financial risk

Benchmarking Access to Healthcare in the EU

357 protection, access to quality essential health-care services and access to safe, effective,
358 quality and affordable essential medicines and vaccines for all” (UNDP 2015).

359 A second set of reasons are instrumental, related to the pursuit of the EU’s fundamental
360 goals. Thus, it is now recognised that modern healthcare can do much to prolong life and
361 to prevent disability and suffering, an objective that is implicit in the Treaty obligation to
362 ensure that a high level of human health protection shall be ensured in all of the Union’s
363 policies and activities. It is also accepted that health contributes to economic growth,
364 through enhanced productivity and reduced losses from the workforce, and by avoiding
365 the adverse economic consequences of catastrophic expenditure on healthcare (Suhrcke,
366 McKee et al. 2005). Third, inequalities in health undermine progress in reducing social
367 exclusion (Marmot, Friel et al. 2008).

368 There are also many reasons why it is in the interests of national governments to
369 minimise unmet need. Thus, at least for now, European citizens, in opinion polls and
370 through their choices at the ballot box, have expressed their support for the welfare
371 state, including the provision of universal health care either by government, social
372 partners or others, within a statutory framework (Missinne, Meuleman et al. 2013). It is
373 also in the interests of those providing health care to minimise unmet need, as a failure
374 to do so will often be more expensive in the long run, as illustrated by studies that have
375 looked at what are called ambulatory care sensitive conditions, whereby failure to
376 identify and treat conditions at an early stage allows them to progress and develop
377 complications that require much more complex and costly treatment (Purdy, Griffin et al.
378 2009).

379 Taken together, these considerations create a clear justification for establishing a right to
380 good quality care. However, the challenge then is how to operationalise this right, and in
381 particular to determine how it should be defined, monitored, and where lacking, how it
382 can be addressed. This is important because, for many reasons, it cannot be assumed
383 that simply by making health care available all needs will be met. In particular, it is now
384 well recognised that health care is subject to market failure (Arrow 2001); if viewed as a

385 tradable commodity health care in a free private market will not reach an equilibrium at
386 a point that maximises health gain and social inclusion.

387 There are several reasons for this. First, need may not be translated into demand, with
388 the most vulnerable in society often least able to express their need as demand. Second,
389 many of the characteristics of a perfectly competitive market, such as symmetry of
390 information between the patient and the health care provider, and the absence of
391 externalities do not apply. These issues have given rise to what has been termed the
392 inverse care law, which states that those in most need are least likely to have it met
393 (Hart 1971).

394 The challenge of operationalising the concept of unmet need, which is in itself
395 considerable given the many methodological issues involved, and which will be discussed
396 later, is complicated further by the qualification in the Charter. Thus, reflecting the
397 Treaty requirement that "Union action shall respect the responsibilities of the Member
398 States for the definition of their health policy and for the organisation and delivery of
399 health services and medical care, the right is to be interpreted "under the conditions
400 established by national laws and practices". In practice, this raises issues of entitlements
401 to care and, specifically, who is considered to make up the population to whom the right
402 applies. For some groups, this is uncontroversial, such as citizens resident in the Member
403 State. For others, such as undocumented migrants, it is often highly contested (Legido-
404 Quigley, Urdaneta et al. 2013, Hiam and Mckee 2016).

405 **3.2. Why was this opinion requested?**

406 This opinion has been requested to support a process of benchmarking Member States,
407 so it is appropriate to reflect on what this means. Benchmarking provides an opportunity
408 for Member States to learn from experiences elsewhere, reflecting on progress made by
409 others and how they have achieved it, offering scope for learning from different
410 experiences, of both good and bad practice and, where possible, to adopt those that
411 work, taking account of differences in context.

Benchmarking Access to Healthcare in the EU

412 This has certain implications. It is not enough to collect information for the sake of it,
413 especially as this requires considerable effort and investment in resources. This
414 investment can only be justified if it leads to improvements. Thus, benchmarking
415 requires that the collection of information on performance is accompanied by an
416 understanding of what policies and processes are effective in bringing about
417 improvements, what strategies can achieve the necessary changes in behaviour, and
418 what characteristics of the healthcare environment facilitate or impede change.

419 Unfortunately, few health systems place a priority on organizational learning, so the
420 same problems are often repeated in different settings. The exchange of ideas on how to
421 improve established practices is rarely given the priority accorded to the introduction of
422 new ones (World Health Organization 2008).

423 Benchmarking is a continuous process, which enables organizations to strive for and
424 even surpass previously determined standard. In this context, it should not be
425 considered as a means of ranking the performance of health systems, although
426 comparative data on performance can be useful for many purposes. Rather it should be
427 viewed as a systematic process of searching for best practices, innovative ideas, and
428 effective operating procedures that lead to improved performance. This requires
429 information, but also the motivation to change, encouraged by a supportive culture and
430 knowledge of what works.

431 **3.3. Defining need**

432 A useful starting point is to define the need for health care. One of the most widely used
433 definition is views need as "the ability to benefit from health care" (Stevens and Gillam
434 1998). This has several obvious implications. First, an individual must have a condition
435 that renders him or her in less than good health. Second, there must be a treatment
436 available that can improve the health of the individual concerned. This need not
437 necessarily mean that there is the means to cure their condition; it may instead be
438 sufficient for there to be the means to alleviate their suffering. However, it also implies
439 that there are no other reasons why they might not benefit from care. For example, a

Benchmarking Access to Healthcare in the EU


440 treatment may be available that could extend life from 5 years to 10 years. However, if
441 the individual concerned has a separate life-threatening illness, with a life expectancy
442 measured in months, then they clearly do not have the ability to benefit from treatment.
443 This does, however, raise more complicated issues. Thus, interventions requiring strict
444 adherence to treatment or lifestyle modification may be questioned when, for whatever
445 reason, the individual concerned is unable to adhere to the recommended treatment.
446 The challenges lie in deciding where to set the boundaries. Thus, in some countries,
447 nonurgent treatment is being denied to those who are smokers or who are obese. The
448 issues raised are beyond the scope of this report, but do demand a wide-ranging public
449 discussion. It is, however, the view of the Expert Panel that, while such decisions may be
450 justifiable on clinical grounds, in that the condition or actions of the patient mean that
451 the treatment is very likely to be ineffective (based on objective evidence), there is no
452 case whatsoever for making them on moral grounds.

453 There is now extensive literature on how need for health care can be measured but, in
454 brief, the task is often quite challenging. First, in many cases, the individual concerned
455 may not realise that they need health care, as is the case with someone who has
456 undiagnosed high blood pressure. Second, even when their condition is symptomatic, it
457 may be necessary to undertake complex, and in some cases, painful or uncomfortable
458 investigations to make a precise diagnosis, and therefore determine whether there is an
459 effective treatment for the condition, and which, by extension, they have a need for.
460 Third, there is the potential for supplier-induced demand, in which an individual may not
461 actually need care, but is advised by a health worker that they do. This situation may
462 arise where that health worker can profit from the administration of unnecessary
463 treatment. The Scottish general practitioner Margaret McCartney has coined the term
464 "patient paradox" when she realised that, at a time when she was struggling to obtain
465 access to essential care for many of her patients from a National Health Service under
466 severe financial pressure, she was being deluged with advertisements from private
467 companies offering screening and treatments that had no evidence of effectiveness

Benchmarking Access to Healthcare in the EU

468 (McCartney 2013). Another example comes from Italy. While patients in many Italian
469 regions complain about unacceptable waiting times for diagnostic imaging services, in
470 particular computerised tomography and magnetic resonance imaging (MRI)
471 examinations, the use of these examinations is among the highest in the world, although
472 there is substantial inter-regional variation (Figure 3-1).

473 **Figure 3-1 Variation in rates of musculoskeletal MRIs among those aged 65 or above in**
474 **regions in the Italian Regional Collaborative, 2015**



475

476 Source: Indicator calculated for a network of Italian Regions by the MeS-Lab (Sant'Anna
477 School of Avanced Studies) – year 2015. These data are public available at the
478 link <http://performance.sssup.it/netval/>

479 There are many reasons for variation on this scale (Wennberg 1999, Appleby, Raleigh et
480 al. 2011), which may reflect overuse or underuse. It cannot be assumed that lower use
481 equates to unmet need; there is clear evidence from many countries that some care is
482 inappropriate. Well-known examples include the use of diagnostic tests (Kachalia, Berg
483 et al. 2015) and elective procedures that yield little or no health gain (McKee, Whatling
484 et al. 2005). Thus, it is important to undertake a comprehensive assessment of the
485 situation to put in place the most efficient strategies (Nutti and Vainieri 2012). What is

Benchmarking Access to Healthcare in the EU

486 necessary is to ensure that people who might benefit most from a service are those who
487 are actually receiving it (Gray, Airoidi et al. 2017). It is important to recognize that what
488 is portrayed as unmet need may, in some cases, reflect inappropriate expectations or
489 supplier-induced demand, especially where those providing the service have financial
490 incentives for over use. In this context, it is important to take account of the
491 questionable ethics of the extensive marketing of many products of unproven
492 effectiveness, including many alternative treatments, such as homeopathy (Shahvisi
493 2016).

494 Given these challenges, research on need for specific types of health care has, in
495 general, been limited to a few conditions with certain characteristics. These
496 characteristics are that the condition can be recognised accurately by the individual
497 affected, that an effective treatment exists, and there are clear objective criteria for
498 determining whether the individual concerned will benefit from treatment. Typically,
499 research has looked at need for certain forms of non-urgent surgery. Studies of
500 osteoarthritis of the hip (Wilcock 1979) and benign prostatic hypertrophy (Sanderson,
501 Hunter et al. 1997) have first developed a symptom scale on which each potential
502 patient can be placed. Clinical judgement, typically based on formal consensus
503 development methods (Black, Murphy et al. 1999), identifies a point on the scale above
504 which the individual is deemed to have an objective clinical need for treatment. The
505 point selected on the scale reflects that at which the net benefits of treatment outweigh
506 the risks. The scale can then be used in a population-based survey to identify the
507 number of individuals in the population who meet this clinically defined criterion for
508 treatment. However, certain challenges arise. First, the individual may have other
509 coexisting conditions that increase the risk of treatment. Second, some individuals who
510 meet the criteria may, as result of personal preference, decline an invitation to be
511 treated. Such individuals, while meeting the objective criteria, would be deemed not to
512 be in need of treatment. However, this approach is only practical in the context of
513 epidemiological research studies.

Benchmarking Access to Healthcare in the EU

514 While epidemiological needs assessment, as described in the previous paragraph, can
515 provide valuable information in a defined population, international comparisons confront
516 another problem in that the reference population may differ among countries. Thus, as
517 the Charter of Fundamental Rights notes, the right to health care is granted under the
518 conditions established by national laws and practice, and Member States with different
519 resources can provide different standards for the acceptable level of care as long as this
520 is done in a way that is non-discriminatory. What this means is that, in each Member
521 State, entitlement to health care varies. In some, it is based on residence, for example
522 in the National Health Service in the United Kingdom. In others, it is related to affiliation
523 to an insurer. This insurer may be a private company or a sickness fund, and enrolment
524 may be optional or compulsory. Entitlement to care is also often related to citizenship,
525 and in particular to migration status. Thus, in many countries, undocumented migrants
526 will be excluded. This problem extends to those who are entitled to care in some
527 countries but who are unable to realise this entitlement because of problems in proving
528 it. One of the best-known examples is the situation faced by Roma in several countries,
529 who face major obstacles to obtaining the appropriate documentation to demonstrate
530 their citizenship and entitlement to services (Kuhlbrandt, Footman et al. 2014, Arora,
531 Kuhlbrandt et al. 2016). However, there are many other examples, such as migrants
532 who, while entitled to care, struggle to establish it, or those with mental health problems
533 who face similar challenges. This issue was discussed in detail in the Expert Panel's
534 report on access to care (Expert Panel on effective ways of investing in Health 2016).

535 In practice, some of the technical challenges of measuring need, but not the political
536 questions of who is covered, have been circumvented by adopting a simple, pragmatic
537 approach, whereby individuals are asked whether they perceive themselves to have a
538 need for health care, although this is not usually defined. They are then asked whether
539 they have sought and obtained treatment for it. Those who have not obtained such
540 treatment are considered to have unmet need for health care. While this approach is
541 pragmatic, it has obvious conceptual limitations, as the preceding discussion shows. A

542 key point is whether there can be unmet need for some types of health care with very
543 small but positive benefits and with very high social costs of providing them, taking into
544 account the “adequate” care qualification mentioned above. The notion of adequate care
545 involves some judgement, which may include consideration of the scarcity of resources
546 required to provide for small benefits of access to health care. Still, the current
547 advantages, including availability, of self-reported measures of unmet needs justify its
548 use. The source of such data is discussed in the following section.

549 **3.4. How is unmet need measured at a European level?**

550 The primary source of comparative data on unmet need for health care is the European
551 Union Survey of Income and Living Conditions (EU-SILC). This survey has been
552 undertaken annually, since 2005, in all Member States and the results formed the basis
553 of many indicators in widely used databases (Arora, Karanikolos et al. 2015). The
554 surveys ask respondents whether they have had a need for individual health services,
555 defined as examination or treatment by a physician or equivalent professional, but has
556 not been met because of cost, distance, or waiting lists, with the same question asked
557 about dental care (Box 3-1).

558

559 **Box 3-1** Questions on unmet need in EU-SILC (UK questionnaire)

560 Was there any time in the last 12 months when, in your opinion, you personally needed
561 a medical examination or treatment for a health problem but you did not receive it?

562 1. Yes

563 2. No

564 What was the main reason for not receiving the examination or treatment (the most
565 recent time)?

566 1. Could not afford to (too expensive)

567 2. Waiting time

568 3. Could not take time because of work, care for children or for others

569 4. Too far to travel/no means of transportation

570 5. Fear of doctor/hospitals/examination/ treatment

571 6. Wanted to wait and see if problem got better on its own

572 7. Didn't know any good doctor or specialist

573 8. Other reasons

574

575 Like all surveys, however, the data are subject to certain limitations. Thus, the sample
576 size is relatively small, limiting scope for sub-group analysis, especially when the sample
577 is already reduced by limiting it to those who report need for health care. Second, EU-
578 SILC data are not fully representative of the population. Specifically, they exclude the
579 institutionalised population, such as those living in health and social care institutions.
580 They also tend to exclude those who are homeless. Both groups are likely to have worse
581 health (and worse access) than the general population. Moreover, while it is intuitive
582 that those who are homeless also have high levels of unmet need, there is also cause for
583 concern that, in some countries, those who are in long-term care may also lack
584 appropriate treatment and, as a result, experience unmet need. Further problems relate
585 to other institutionalised populations, such as prisoners, who often have particular health
586 needs and are also excluded from surveys. Importantly, the surveys do not provide
587 specific information on unmet need for mental health services or for social care, with the

Benchmarking Access to Healthcare in the EU

588 latter a particular problem in countries where much of the care provided for people with
589 dementia is in the social care sector. There are also problems of comparability as the
590 questions and the means of data collection are not exactly the same in every country.
591 Another problem is that the question, as asked, provides an upper bound on unmet
592 needs. This can become problematic when developing targets (Box 3-2).

593 **Box 3-2 Challenges in interpreting the EU-SILC question on unmet need**

594 We begin with two different people:

595 Person A: felt the need to obtain health services 3 times in a year and actually accessed
596 them on 2 of the 3 occasions so the answer to a question about any episode of need that
597 was not satisfied is "yes".

598 Person B: the need to obtain health services on one occasion but did not access them, so
599 again the answer is "yes".

600 If calculated in terms of episodes of need, these two people have 4 of which 2 are
601 unmet, so unmet need should be 50%.

602 If calculated in terms of people having at least one episode of not having access, there is
603 100% unmet need.

604 Then, person C is added, with 2 episodes of need for health services, both of which lead
605 to care. If measured as people, the unmet need is 66%, while if measured as in episodes
606 it is $2/6 = 33\%$.

607
608 One solution would be to ask respondents what happened the last time they felt sick and
609 not whether they had at least one episode of missing care (for whatever reason).
610 However, this does not address the next point as the EU-SILC data do not distinguish
611 between unmet need for first contact and for subsequent care. Need for the latter may
612 not be met when waiting lists for interventions are long and people are treated outside a
613 clinically acceptable time window, when patients receive less care than required, for
614 example through premature discharge or failure to provide necessary treatment, when

Benchmarking Access to Healthcare in the EU

615 patients are kept in hospital inappropriately because there is no space in social care or
616 other more appropriate settings, or when informal care inappropriately replaces formal
617 care because of an absence of the latter. Thus, although comparative data on unmet
618 need at European level are routinely collected, there are some concerns about their
619 validity, coverage, and meaning.

620 An alternative approach to measuring need through health outcomes is to use self-
621 reported health measures, where each individual in a survey is asked to rate her health
622 as, for example, very good, good, bad, very bad. This information is also available in EU-
623 SILC but suffers from the major limitation of saying nothing about whether the poor
624 health is due to unmet need for health care.

625 Another approach is to infer the extent of health need by looking at health outcomes.
626 There are several approaches to assessing population health outcomes. The one used
627 most often in assessing the contribution of health care involves variants on the theme of
628 mortality amenable to health care, or avoidable mortality (Nolte and McKee 2011). A
629 variety of versions are used by different organisations, including the OECD, the
630 Commonwealth Fund in the USA, and the NHS in England. The most recent iteration has
631 been developed by the Institute of Health Metrics at the University of Washington (GBD
632 2015 Healthcare Access and Quality Collaborators 2017). This goes beyond previous
633 approaches by standardising for risk factors in a population and by creating a frontier
634 quantifying what a country might expect to achieve given its level of development.
635 Summary results of the most recent analysis are shown in Table 3-1. The HAQI scores
636 are on a scale from 0 to 100, with higher scores indicating better performance. The
637 frontier is calculated as what could be expected based on a combination of national
638 income, level of education, and fertility. As can be seen, most Member States achieve or
639 exceed what would be predicted but not all do.

640

Benchmarking Access to Healthcare in the EU

641 **Table 3-1 Health Access and Quality Index scores for EU Member States, 2015**

Member State	HAQI	HAQI Frontier	Difference
Austria	88.2 (87.3-89.0)	90.0	1.8
Belgium	87.9 (86.8-88.8)	89.6	1.8
Bulgaria	71.4 (69.6-73.1)	84.8	13.5
Croatia	81.6 (80.5-82.7)	82.9	1.2
Cyprus	85.3 (84.2-86.4)	89.5	4.2
Czech Republic	84.8 (83.9-85.7)	90.2	5.3
Denmark	85.7 (84.7-86.7)	90.9	5.2
Estonia	81.4 (80.1-82.6)	88.3	6.9
Finland	89.6 (88.6-90.5)	90.2	0.6
France	87.9 (86.9-88.9)	86.7	--
Germany	86.4 (85.4-87.3)	90.6	4.3
Greece	87.0 (86.1-87.9)	85.9	--
Hungary	79.6 (78.2-81.0)	87.6	8.0
Ireland	88.4 (87.5-89.3)	90.0	1.6
Italy	88.7 (87.8-89.6)	88.1	--
Latvia	77.7 (76.3-79.3)	88.4	10.6
Lithuania	76.6 (75.5-77.9)	87.0	10.4
Luxembourg	89.3 (88.4-90.2)	90.9	1.6
Malta	85.1 (84.0-86.1)	84.5	--
Netherlands	89.5 (88.6-90.4)	90.3	0.8
Poland	79.6 (78.2-81.0)	88.8	9.2
Portugal	84.5 (83.6-85.5)	80.5	--
Romania	74.4 (72.7-76.0)	84.0	9.6
Slovakia	78.6 (77.3-79.9)	88.5	9.9
Slovenia	87.4 (86.5-88.4)	88.0	0.6
Spain	89.6 (88.8-90.3)	85.7	--
Sweden	90.5 (89.6-91.4)	90.2	--
United Kingdom	84.6 (83.8-85.4)	90.3	5.7

642

643 Source: (GBD 2015 Healthcare Access and Quality Collaborators 2017)

644


645 In summary, while the formal definition of need for health care, and consequently the
 646 level of unmet need in a population is clearly defined, there are major challenges in
 647 operationalising a measure of it. These relate to definition of the population that is
 648 included, achieving a representative sample of the population, and creating a practical
 649 but verifiable definition of unmet need. We are also not aware of alternative surveys
 650 which measure unmet need with the same degree of EU country coverage, which limits
 651 the scope for alternative indicators in the short run.

652 **3.5. Trends in unmet need in Europe**

653 Trends in unmet need for health care were described in detail in the expert panel's
654 previous report on access to health services (Expert Panel on effective ways of investing
655 in Health 2016). These have been updated and are shown in Figure 3-2. In brief, there
656 are large variations in the percentage of people reporting unmet need for health care,
657 varying from under 1%, in countries Austria and Slovenia, to over 19% in Latvia.

658 **Figure 3-2 Percentage reporting unmet need for health care in Member States 2015**

659



660


661 Source: Calculated from EU-SILC data

662

Benchmarking Access to Healthcare in the EU

663 Overall, the percentage of people reporting unmet need for health care has fallen
664 substantially from 2005 until 2010, after which it began to increase, possibly due to the
665 change in financial climate (Reeves, McKee et al. 2015), although the most recent trend
666 indicates some recovery. When disaggregated, there are very large differences according
667 to the characteristics of respondents, in particular by socioeconomic status, as shown in
668 Figure 3-3, which is an updated version of a figure in the previous report.

669 **Figure 3-3** Share of people reporting unmet need for health care due to cost,
670 **travel distance, and waiting list by income, age, gender, education and employment**
671 **status, EU 28, 2005-2015**



672

673 Source: Calculated from EU-SILC data

674 Thus, in 2015, the percentage of those in the richest quintile reporting unmet need was
675 below 2% while in the poorest quintile it was over 5%. Rates of unmet need are about
676 50% higher among people aged over 65 and among the overall population, are slightly
677 higher among females than males, and substantially higher among those with less
678 education or who are unemployed. The changes over time have had a substantial impact
679 on European citizens. One study estimated that, in 2013, an extra 1.5 million people
680 experienced unmet need compared to 2008, although with the earlier rate of decline had
681 continued, the gap would be 7.3 million people (Reeves, McKee et al. 2015). The poor

Benchmarking Access to Healthcare in the EU


682 were most affected; the increase in unmet need after 2010 was approximately 6 times
683 larger among those in the poorest quintile compared to those in the richest quintile.

684 A number of studies have been undertaken in individual countries to understand the
685 factors underlying these changes (Kentikelenis, Karanikolos et al. 2014, Karanikolos,
686 Gordeev et al. 2016, Legido-Quigley, Karanikolos et al. 2016). These vary, but include
687 introduction or increases in co-payments and reduced access to facilities, either through
688 limited opening hours or closures, necessitating longer travel distances.

689 It would be expected that, for given supply of services, unmet need will be higher when
690 need is higher. In figures 3-4 and 3-5 it can be seen that there is a tendency, albeit
691 weak, for there to be greater unmet need in countries where more people report poor
692 health or where the overall mortality rate is higher.

693 **Figure 3-4 Unmet need and % of people reporting poor health, 2015**

694



695

696 Source: calculated from statistics compiled by EUROSTAT and EU-SILC data


697

698

699

Benchmarking Access to Healthcare in the EU

700 **Figure 3-5 Unmet need and total mortality per 100,000 (2014)**



701

702 Source: calculated from statistics compiled by EUROSTAT and EU-SILC data


703 It would also be expected that, for a given level of need, unmet need will be lower in
704 systems with more resources devoted to health care. In figures 3-6 and 3-7 we show
705 that unmet need tends to be lower in wealthier countries and those that spend a greater
706 proportion of national income on health (spending involves prices and costs of resources,
707 meaning that for the same physical resources and care provided, different prices across
708 countries may imply different spending levels; adjusting for this aspect will likely not
709 change the picture).

710

711

Benchmarking Access to Healthcare in the EU


712 **Figure 3-6 Unmet need and GDP per capita, 2013**



713

714 Source: calculated from statistics compiled by EUROSTAT and EU-SILC data

715 **Figure 3-7 Unmet need and Total Health Expenditure (PPS, 2014)**



716

717 Source: calculated from statistics compiled by EUROSTAT and EU-SILC data

718 **3.6. Reasons for unmet need**

719 There is an extensive body of literature on the reasons for unmet need for health care,
720 much of which was summarised in the Expert Panel's previous opinion on access to care.
721 These can be illustrated with reference to two systematic reviews examining barriers to
722 the receipt of effective care for hypertension (Maimaris, Paty et al. 2013, Khatib,
723 Schwalm et al. 2014). These identified barriers at several levels, summarised in the
724 previous report of the Expert Panel on access to care as:

725 *"Access is a multi-dimensional issue. Barriers to access can be found at the level of*
726 *individuals, health service providers and the health system. Access is also affected*
727 *by public policy beyond the health system – especially fiscal policy, but also social*
728 *protection, education, employment, transport and regional development policy.*
729 *Survey data suggest that financial barriers are the largest single driver of unmet*
730 *need for health care in the European Union."*

731 Thus, the extent to which a condition is regarded as 'abnormal' and requiring treatment
732 varies, reflecting cultural norms and expectations. The decision to seek treatment may
733 be influenced by the opportunity cost of doing so, for example where someone must
734 travel long distances or will lose income if they take time off work. Some individuals may
735 not be aware that there is a treatment available for their condition. Finally, the decision
736 to seek care often requires recourse to financial resources, a supportive social network of
737 family, friends, and informal carers, access to transport, and information about how to
738 navigate the system. Other barriers exist in health facilities and in interactions with
739 health workers. These include lack of knowledge by health workers, inaccessibility of the
740 facilities, and lack of equipment or supplies. A final set of barriers act at the level of the
741 health system, including the overall level of funding, availability of prepayment
742 mechanisms, such as insurance coverage, the services covered, and mechanisms to
743 ensure that appropriate services are available in each community.

744 **3.7. Proposal for an overall target**

745 Pragmatically, any target to reduce unmet need must be obtainable from existing
746 sources. In practice, this means the EU-SILC, which is the only survey covering
747 dimensions of unmet need for all EU countries, notwithstanding its limitations. However,
748 this begs the question of what the target should be.

749 Given that Member States have already subscribed to the right to health care, the
750 implication should be that the adequate level of unmet need should be zero, or close to
751 it. It does not mean that all needs should be met whatever the cost of providing that
752 health care. There is clearly an opportunity cost to providing any care. In a system with
753 constrained resources, it is necessary to set priorities that take account of both the cost
754 and the benefit of intervening, although this should be done in a way that is transparent,
755 using processes that ensure that the bodies involved are accountable to those whose
756 care they are responsible for. This is a complex and contested area, involving both
757 technical and political considerations, and goes far beyond what can be addressed in this
758 report.

759 For the present purposes, what is important to note is that several countries have
760 reduced rates to under 1%. The International Covenant established the principle of
761 progressive realisation (Sridhar, McKee et al. 2015), which would imply that a Member
762 State could set as a target a higher figure initially, but subject to periodic revisions
763 consistent with progress over time. However, this would mean that several Member
764 States will already have achieved this target.

765 **3.8. Proposal for national targets**

766 The terms of reference for this report asked for both a target for the EU as a whole, and
767 a target that can be adapted to the context of each Member State. Our approach was
768 informed by the SMART mnemonic, widely used in setting targets (Doran 1981). This
769 proposes that targets should be:

- 770 • Specific – they should target a specific area for improvement;

Benchmarking Access to Healthcare in the EU

- 771 • Measurable – they can be quantified, or at least there should be indicators of
772 progress;
- 773 • Assignable – responsibility for achieving them should be specified;
- 774 • Realistic – results can realistically be achieved, given available resources;
- 775 • Time-related – the time to achieve the result(s) should be specified.

776 In this case, several of these elements are prespecified. Thus, the target relates to
777 unmet need for healthcare, which is measured by using data from the EU-SILC surveys.
778 Legally and politically, the target is assumed by the Member States, although how they
779 further assign responsibilities is a matter for them under the principle of subsidiarity. The
780 remaining questions relate to levels of achievement and timings that are realistic.

781 Given the long-established principle of adopting policies that move towards convergence
782 within the EU, there is a strong argument for setting a target that is in the vicinity of
783 that already achieved by the most privileged group in the best performing Member State
784 (i.e. below 1% in 2013). However, recognising the different starting positions of each
785 Member State, it seems reasonable to argue that individual national targets should be
786 set that are challenging but achievable improvements on what has already been attained
787 (Vainieri et al 2016). If a 1% target is agreed, then the timing by which it should be
788 achieved will need to be considered. However, this will clearly need appropriate
789 resources, the allocation of which is a fundamentally political issue at the national level.
790 For this reason, it is beyond the remit of this Expert Panel to set a date for this target to
791 be achieved. However, it should be sufficiently ambitious. An extrapolation of trends in
792 the on the weighted EU average between 2005 and 2015 suggest that, without further
793 actions, this will only be achieved in 2052. It seems reasonable to suggest that a
794 reasonable target might be within about 10 years. This would be challenging but
795 achievable. To bring the unweighted EU average rate below 1% by 2025 would require
796 the rate of decline to be 2.3 times faster than it has been between 2005 and 2015.

Benchmarking Access to Healthcare in the EU

797 Clearly, progress against the required performance would be monitored regularly in the
798 intervening period.

799 As to the national targets, again, it is ultimately a political decision as to where the
800 target should be set. After detailed discussion, we believe that the following approach
801 could be appropriate, on the basis of considerations of feasibility, simplicity, and data
802 availability. This envisages that the initial target would be defined as the median value
803 achieved by the best performing tercile of Member States (this could also be the best
804 performing quartile or quintile – the choice will make little difference). Given the intrinsic
805 variability associated with the small numbers in the surveys, we propose that this should
806 be averaged over several years (between 3 and 5). This means that some Member
807 States will already have achieved this target, but most would not have. Recognising that
808 it may be more difficult for those further from the target to make progress, we propose
809 that each would be expected to close the gap between its current performance, averaged
810 over 3 years, and the target by certain percentage over a defined period of time. We
811 propose that this percentage might reasonably be 50% and the time period three years,
812 while recognising that the precise figures will be subject to political agreement.

813 This approach is set out mathematically in Box 3-3. The benchmark figure is defined as
814 the median value obtained in countries in the lowest tercile of unmet need. To allow for
815 fluctuations related to sampling, this is averaged across the three most recent years for
816 which data are available for all countries (2013-15). Each country's level of unmet need
817 in 2015 is then calculated. In some cases, this causes a country in the best performing
818 tercile over the past three years to be above the benchmark if its reported performance
819 has deteriorated. Those countries exceeding the benchmark are then given a target of
820 reducing the gap between the score in 2015 and the benchmark by 50%. This would
821 allow every Member State to have a specific target that is both challenging and fair. The
822 implications for each Member State are shown in Figure 3-8.

823

824 **Box 3-3 Possible formula for generating target for unmet need**

825 We denote TG_t as the overall target (across all EU member states) in period t , and UN_{it}
826 as unmet need of country i in period t .

827 Then, we can write the target for country i in period t , TG_{it} , as a function of the same
828 country unmet need and the overall target:

$$829 \quad TG_{it} = \max(TG_t, TG_t + (x\%) * (UN_{it} - TG_t))$$

830 where $x\%$ is the adjustment parameter required to close the gap between unmet need in
831 country i in period t in k years (e.g. 50% of the gap in 5 years, 40% of the gap in 4
832 years etc.).

833 The overall target could be computed as a function of the unmet need across all
834 countries in the previous years. Suppose for example that we use the median unmet
835 need averaged across the three previous years. Then,

$$836 \quad TG_t = \frac{1}{3} \sum_{t-3}^{t-1} (\text{median } UN_{it} \mid i \text{ in } I)$$


837 where I is the reference set of EU countries.

838

839

Benchmarking Access to Healthcare in the EU

840 **Figure 3-8** Gap between level of unmet need in 2015 and benchmark based on best
841 performance in past three years
842



843

844 A note of caution is, however, required. The small size of the samples must be taken into
845 account, in that confidence intervals will have to be computed to assess the extent to
846 which unmet need is statistically different from a reference category (which could be
847 mean or median unmet need in all Member States or in a group with low unmet need or
848 a previous level of unmet need in the Member State concerned), though this would
849 require a regression based approach. A single (final) target for all countries means that
850 are no differences in countries that justify a principle of target differentiation.

851 **3.9. Inequalities within Member States**

852 The scenarios above refer to overall levels of attainment within a Member State, yet as
853 noted above, an even greater problem is the degree of variation within them, on grounds
854 of age, gender, education, employment status, and potentially many other factors. Thus,
855 a second question to be addressed is the extent to which overall national targets should
856 be supplemented by those examining inequalities between groups, defined in various
857 ways.

Benchmarking Access to Healthcare in the EU

858 The groups that are disadvantaged will vary among countries, reflecting differences in
859 ethnic mix, history, and much else. Thus, it seems appropriate that the different types of
860 inequities in access on which attention is focussed should take account of national
861 context, with reporting of a range of quantitative and qualitative assessments as
862 appropriate. Thus, while gender is likely to be of interest everywhere, it may be
863 important to consider issues such as age, rural habitation, or specific ethnicities only in
864 some settings. This has certain implications. A comprehensive strategy to reduce unmet
865 need must understand the nature of disadvantage in each country and devise strategies
866 that explicitly seek to address it. This will often require bespoke systems of data
867 collection, coupled with a detailed understanding of the cultural issues involved in
868 health-seeking behaviour. This national approach is consistent with the accumulated
869 literature on targets points to a need to avoid a top-down approach when setting them
870 (Wismar, McKee et al. 2008). Ideally, each country will recognise the importance of
871 making progress in reducing inequities in unmet need and will set a plan which is
872 compatible with its other priorities, and also with a recognition of the limitations of the
873 data. Even for countries currently meeting the eventual target set, its monitoring is
874 relevant to detect and act early on future deviations. It may also help to fine tune
875 policies.

876 **3.10. Second level indicators**

877 As noted above, there are many reasons why some individuals, and some groups within
878 populations experience greater levels of unmet need than others. These issues were
879 explored in considerable detail in the Expert Panel's previous report on access to care
880 (Expert Panel on effective ways of investing in Health 2016). They followed three broad
881 categories, affordability, availability (and accessibility) and acceptability (user
882 experience). Each, in turn, is separated into three further headings. Thus, affordability
883 can be ensured by having financial resources that are linked to health need, services
884 that are affordable for everyone, and ensuring those services are relevant, appropriate,
885 and cost-effective. Availability encompasses accessibility to acceptable, well-equipped

Benchmarking Access to Healthcare in the EU

886 facilities within easy reach and adequate provision of health services, staffed by health
887 workers with the right skills in the right place, who have access to quality medicines and
888 devices are available at fair prices.

889 These categories suggest several second level indicators, each of which can help to
890 explain overall levels of unmet need in a country. However, for these purposes, it is
891 necessary to make a decision about how parsimonious such a set of indicators should be.
892 Thus, it could be argued that a very large number of existing measures have some
893 relationship to need for health care and the extent to which it is met, such as the share
894 of national income being spent on health or the numbers of health workers per head of
895 population. However, in all of these cases, the relationship is somewhat indirect, and in
896 many cases, the key issue is the distribution rather than the absolute level in a country.
897 Consequently, it is suggested that the secondary indicators be few in number. While it is
898 not necessarily desirable for indicators to be driven entirely by availability of data, there
899 is, however, an argument for seeking to make them congruent with existing data, to the
900 extent possible. In this context, the key consideration is the categorisation of reasons for
901 unmet need in the EU SILC data. Respondents are given three options, with unmet need
902 being attributed to cost, travel distance, or waiting lists. These map nicely onto the three
903 broad categories identified in the Expert Panel's earlier report. Thus, cost equates to
904 affordability, travel distance captures aspects of availability, and waiting time is a key
905 dimension of user experience. The Expert Panel believes that all of these are important
906 and should be monitored at a European level, although the importance on individual
907 measures will vary among Member States depending on the progress they have made
908 previously and what still needs to be done. We will now consider each of these in turn.

909 Before doing so, it is however, necessary to reflect upon the point at which need is
910 considered to have been met. For the patient, this is relatively straightforward, as it is
911 the point at which the condition is cured or symptoms alleviated, even if the ultimate
912 outcome is death. However, there are enormous practical difficulties in operationalising
913 this for routine measurement. Instead, it is more usual to define needed as having been

914 met when the patient has made first contact with the health system. It is, however, fully
915 recognised that this is a very incomplete, and arguably irrelevant measure of met need,
916 even more so at a time when interactions with health system are assuming many non-
917 traditional forms, including via the Internet.

918 This is an issue that will require further consideration. Thus, the growth of chronic
919 disease and multi-morbidity means that many patients will be on a prolonged journey
920 through the health system, and for them, the crucial question will be the extent to which
921 their needs are met at each point on that journey. The challenges are often exacerbated
922 for those with mental health or social care needs. It is not, however, clear, how this can
923 easily be addressed in a consistent way using survey data. There is potential to use
924 administrative data on regular contacts with patients at all levels of care for the purpose
925 of following the patients' journey within the health care system, at least in systems
926 where there are unique personal identifiers that are used consistently.

927 A related issue is the quality of care that is provided. This also raises the issue of
928 asymmetry of information. Thus, a patient may have achieved access to a health
929 professional who will provide reassurance that they either do not need treatment or the
930 treatment they are provided with is adequate, yet in practice that treatment is far from
931 adequate. The patient may consider that their need has been met even though it has not
932 been.

933 **3.10.1.Affordability**

934 The episodic nature of health care, whereby most people require care only occasionally,
935 but when they do, it may be extremely expensive, is quite different from consumption of
936 other goods, such as food. Consequently, a comprehensive picture of affordability
937 involves an understanding of how much is spent regularly to ensure access to care, for
938 example through insurance premia how much is paid for each episode of care, for
939 example, payments for consultations or medicines, and the economic impact of severe
940 illness, usually measured as catastrophic expenditure. Some of these measures are, to

Benchmarking Access to Healthcare in the EU

941 some extent, measurable and, in some cases, are already incorporated in routine
942 statistics.

943 There are, however, substantial problems with all of them. First, the amount paid for
944 health care may be concealed within overall taxation. Given that government revenues
945 in countries with national health services are derived from many different sources, it is
946 not simply a matter of taking the share of expenditure for health as a fraction of, for
947 example, income tax. Moreover, in countries with universal coverage, those who are
948 unable to afford regular payments for health care will usually receive additional support
949 through the welfare system. However, for the present purposes, the very existence of a
950 prepayment system will increase the probability that need will be met. Consequently, it
951 is reasonable to focus attention on the other elements of expenditure on healthcare.


952 Co-payments are similarly complex. Often, they vary, according to the type of service
953 provided or the medicines received. There are very frequent exemptions. Thus, in
954 Portugal, where there have been considerable changes in the co-payment regime in
955 recent years, the net result is quite complex because of the extent to which exemptions
956 for some have compensated for higher payments by others (Legido-Quigley, Karanikolos
957 et al. 2016).

958 The OECD define household out-of-pocket expenditure on health as comprising
959 expenditures borne directly by a patient where insurance does not cover the full cost of
960 the health good or service. They include cost-sharing, self-medication and other
961 expenditure paid directly by private households. In some countries, estimations of
962 informal payments to health care providers are also included. Using this definition, the
963 figures for 2015 range from 6.8% of total household expenditure in France to 41.6% in
964 Latvia (Figure 3.9).

965

Benchmarking Access to Healthcare in the EU

966 **Figure 3-9** Out-of-pocket expenditure as a share of final household consumption
967




968
969

970 Source: OECD

971 Figure 3-10 shows out of pocket expenditure as a percentage of total health expenditure.

972

973 **Figure 3-10 Out-of-pocket expenditure as a share of total health expenditure**



974

975 Source: OECD

976 The interpretation of out-of-pocket payments can be problematic. For example, an
 977 individual with private health insurance who visits a specialist several times will have
 978 their needs met but may incur high out-of-pocket payments (as will also be the case
 979 when significant user charges exist in a publicly funded National Health Service). In
 980 contrast, an individual who never visits a doctor will have zero out-of-pocket payments
 981 but, if ill, may have a high level of unmet need. Out-of-pocket payments are the result of
 982 very different institutional arrangements in terms of public-private mix on both funding
 983 and provision. There is also the issue of informal payments, some of which may take the
 984 form of gifts of things that cannot easily be monetarised (Gaal, Belli et al. 2006). There
 985 are also large differences in the elements that make up out of pocket payments. For
 986 example, data from 2014 show that the share contributed by spending on
 987 pharmaceuticals ranges from 16% in Luxembourg to 75% in Romania (OECD 2016).

Benchmarking Access to Healthcare in the EU

988 Thus, they represent a useful indicator but only if combined with a good understanding
989 of the diverse institutional settings in which they originate.


990 The third element is catastrophic expenditure. Yet, although this measure is often used
991 in international comparisons, it is more problematic than is sometimes recognised (Xu
992 2005). First, survey questions vary in asking about different periods in which
993 catastrophic expenditure occurs, with some using a period as short as one week but
994 others up to one year. Second, surveys typically miss those households that forgo
995 treatment because it is unaffordable, thereby avoiding what would otherwise be
996 catastrophic expenditure. Third, although less directly relevant here, illness incurs costs
997 other than direct monetary ones, for example through loss of earnings. Nevertheless,
998 the share of catastrophic out-of-pocket payments in household consumption can be
999 considered as a means to reveal limitations in access to healthcare due the financial
1000 hardship resulting from out of pocket payments.

1001 In practice, data on catastrophic expenditure are not routinely available in all Member
1002 States. They are usually derived from family budget surveys, typically collected every
1003 five years, although with inconsistencies across countries. If used, a number of
1004 alternative definitions would need to be explored (e.g. payment as ratio of non-food
1005 expenditure, income or wealth).

1006 We suggest that affordability as a potential cause of unmet need should be addressed
1007 through i) the EU-SILC data which ask about whether unmet need was due affordability;
1008 and ii) out-of-pocket payments combined with a clear description of the institutional
1009 arrangements that pertain and differences in how the data are collected in each member
1010 State. Figure 3-10 illustrates the potential for using the EU-SILC data, showing the
1011 percentage of respondents reporting unmet need for health care in 2015 due to
1012 unaffordability by Member State.

1013
1014
1015
1016

1017 **Figure 3-11 Unmet need for health care due to unaffordability**



1018

1019 Source: calculated from EU-SILC data

1020 **3.10.2. Availability & Accessibility**

1021 Availability relates to the existence of facilities that provide services that can meet the
 1022 needs of potential patients. Again, this is potentially extremely complicated, as patients
 1023 with complex needs will require highly specialised facilities. Consequently, pragmatically,
 1024 it seems reasonable to consider availability as the existence of facilities meeting some
 1025 basic level of provision, such as primary care clinics. Availability has several dimensions,
 1026 spatial, temporal, and formal. Thus, there is a well-known gravity effect, whereby rates
 1027 of attendance at health facilities fall off markedly with increasing distance. This is a non-
 1028 linear relationship, approximating to the well-known adverse square law, although there
 1029 is some variation according to the nature of the needs being met (McKee, Gleadhill et al.
 1030 1990, Jordan, Roderick et al. 2004). However, to complicate matters, distance can be
 1031 measured in several ways. These measures range from the simple straight line between
 1032 the patient's home and a facility, the so-called crow fly distance, to travel time, which
 1033 varies according to the means of transport available to the individual. Thus, a facility
 1034 that may appear close for someone with their own car may be relatively inaccessible for

Benchmarking Access to Healthcare in the EU

1035 someone dependent on public transport, while in some remote areas, as in Finnish
1036 Lapland, it may be quicker to fly to the capital than to drive to the nearest tertiary
1037 hospital. It should also be noted that, in some cases, people may be willing to trade
1038 what they perceived to be the advantages of living in a remote rural area for access to
1039 healthcare. However, this highlights the need for information on unmet need to be
1040 interpreted in the light of evidence on the travel distances of the population from major
1041 settlements in some countries. A further complication relates to the starting point for the
1042 potential patient. Individuals live their life in complex spaces, encompassing home, work,
1043 and leisure locations. A facility that is close to them at one point in the day may be
1044 distant at another (e.g. while the individual is at work). Conversely, a facility close to
1045 where they live may yet be inaccessible at night if it is only open during working hours.
1046 This leads onto the next point.

1047 The temporal dimension relates to when the facility is open. Thus, in Greece, reductions
1048 in opening hours of clinics were associated with a significant increase in unmet need for
1049 care (Kentikelenis, Karanikolos et al. 2014).

1050 Opening hours should ideally relate to when services are needed, so while emergency
1051 care facilities should be open twenty-four hours a day, routine clinics need not be.

1052 The formal dimension relates to the extent to which services are open only to those with
1053 particular characteristics. This may be insurance status, occupation, or some other
1054 parameter. This may be relevant for groups such as population groups, such as the
1055 homeless, long-term unemployed, undocumented migrants, people with severe and
1056 chronic mental disorders, and people with disabilities.

1057 Measuring the number of facilities across countries is unlikely to be a good measure of a
1058 cause of unmet need. A smaller number of large facilities might provide higher quality if
1059 they benefit of scale and scope economies, and learning-by-doing effects due to larger
1060 volumes, although the literature on the relationship between hospital volume and
1061 outcome is complex (McKee and Healy 2002). There are also definitional issues to obtain
1062 meaningful comparisons of facilities availability across countries. It is also necessary to

1063 take account of appropriateness, as not all facilities will be able to offer care for every
1064 health need.

1065 Availability could also be captured by a measure of the comprehensiveness of the basket
1066 of health services covered in each Member State, but such measures are likely to be
1067 multidimensional and difficult to quantify, making it challenging to and collapse them
1068 into a single measure (Schreyogg, Stargardt et al. 2005).

1069 We, therefore, suggest that availability as a potential cause of unmet need should be
1070 addressed through the EU-SILC data, as these ask about whether unmet need was due
1071 availability. Other existing proxies from existing data collections at member country level
1072 (e.g. OECD Health at a glance) could be used (e.g. beds per capita) but are an imperfect
1073 measure of availability (thus, hospital beds per capita become less meaningful due to
1074 increases in day surgery and ambulatory care).

1075 **3.10.3. User experience**

1076 User experience is also a multidimensional construct. It is subject to numerous biases
1077 and is time dependent. Thus, a service perceived as unacceptable immediately after it
1078 was received may be reassessed more favourably later, and vice versa. It covers all
1079 aspects of the care provided, including both clinical interventions and what might be
1080 described as customer experience, such as the extent to which the patient is welcomed
1081 to the facility, the quality of the facility, encompassing such issues as ease of navigation
1082 around it, comfort, choice and quality of food, and facilities for friends and relatives. It
1083 also includes the extent to which patients' preferences are taken into account. This is
1084 especially challenging. While there is a growing consensus that the decision to intervene
1085 should be taken jointly by the patient and their health provider, or increasingly,
1086 multidisciplinary team of providers, based on the provision of appropriate information,
1087 there are also some patients that would prefer that the choice be taken for them.
1088 Clearly, it is important that all those involved in such decisions find the right balance.

1089 Methods to evaluate user experience have been developed and implemented, such as
1090 the "friends and family" test in the NHS in England. This asks patients whether they

Benchmarking Access to Healthcare in the EU

1091 would recommend a health facility to their friends or family. It draws on the use of this
1092 question in surveys of hotels, restaurants, and the like. From the outset, this measure
1093 faced considerable criticism because of the obvious difference between healthcare and
1094 use of leisure facilities. Subsequent research has shown that it has many flaws, with
1095 responses differing by age, gender, and mode of administration, while in practice, it can
1096 be difficult to obtain satisfactory response rates (Sizmur, Graham et al. 2015).

1097 These considerations make it challenging to operationalise the concept of user
1098 experience. However, it can be considered as equating to the measure of responsiveness
1099 used in the 2000 World Health Report (World Health Organization 2000). This had
1100 several elements, falling into two broad categories. The first category related to respect
1101 for persons, including respect for the dignity of the person, confidentiality, and autonomy
1102 to participate in choices about one's health. The second was client orientation, which
1103 included prompt attention, communities of adequate quality, including cleanliness,
1104 access to social support networks, and choice of provider. All of these factors could, in
1105 theory, impact on whether need is met. Thus, a service that is extremely unresponsive
1106 will act as a deterrent to potential patients, making it more likely that their need will be
1107 unmet. The previous report of the Expert Panel on access to health services noted that:

1108 *"People need to be willing to use available services, and when they use health*
1109 *services, their experience should be as positive as possible because user*
1110 *experience shapes expectations and can influence health care-seeking behaviour in*
1111 *the future. Services that fail to be acceptable to people are likely to be under used,*
1112 *with negative implications for health, efficiency in the use of health system*
1113 *resources and equity in use." (Expert Panel on effective ways of investing in Health*
1114 *2016)*

1115 As noted above, the one aspect that is already asked about in the EU SILC data is
1116 prompt attention, or the extent to which need is unmet because of long waiting lists.
1117 However, there may be a case for requesting that additional questions be included in
1118 future waves of the EU-SILC questionnaires.

Benchmarking Access to Healthcare in the EU

1119 We, therefore, suggest that user experience as a potential cause of unmet need should
1120 be addressed through the EU-SILC data which ask about whether unmet need was due
1121 waiting time, which could be further complemented or validated from OECD data
1122 collection on waiting times from administrative data (Siciliani, Moran et al. 2014). Care is
1123 required in defining the indicator. In a health system, there may be several waiting
1124 times: waiting time for a first appointment, waiting time after receiving a decision to
1125 undertake surgery, the sum of all relevant waiting times (as restricting access to primary
1126 care helps waiting times for surgery as less people reach that stage), etc.

1127 **Box 3-4** **Waiting times for non-emergency treatments across the EU**

1128 Waiting times for non-emergency treatments (such as hip replacement, knee
1129 replacement, and cataract surgery) have been reducing in the recent years in some
1130 countries.

1131 Figure 3-12 provides the inpatient median waiting times for hip replacement (from
1132 addition to the list to treatment by a specialist) over the period 2005-2015 across 15
1133 countries. The United Kingdom and Finland have experienced significant reductions in
1134 waiting times between 2002 and 2010 by combining maximum waiting time guarantees
1135 with sanctions for failure to fulfil the guarantee (Siciliani, Moran et al. 2014).


1136 The data are from administrative sources and are representative of large populations of
1137 patients receiving a specific non-emergency treatment. Countries differ in key reported
1138 indicators. For example, some countries report the mean waiting times, while others only
1139 the median. Moreover, some countries report the waiting time of patients "on the list" at
1140 a point in time (e.g. every quarter), while others report the waiting time of patients who
1141 have been "treated" in a given year (as in the figure below); these will give different
1142 representations of the waiting time phenomenon (Dixon and Siciliani 2009).

1143

1144

Benchmarking Access to Healthcare in the EU

1145 **Figure 3-12** Median waiting time (from specialist assessment to treatment) for hip
 1146 replacement



1147 Source: OECD Health Statistics (2016).
 1148

3.10.4. Inequalities & Inequities

1149 As will be clear from the preceding discussion, to be relevant, measures of unmet need
 1150 should capture both the absolute level and distribution within a population. There are
 1151 different approaches to measuring inequalities. The first is a simple mathematical
 1152 approach, looking at the degree of dispersion of a measure without any presupposition
 1153 as to the underlying reasons. There are a number of statistical approaches, such as the
 1154 sum of differences between all pairs of variables or the sum of absolute differences from
 1155 the mean value (z-score). This approach has the advantage of being applicable in all
 1156 settings but the limitation that it says little about the reason for the degree of dispersion.
 1157 The second involves pre-specifying those characteristics of subgroups within the
 1158 population associated with differences in unmet need. Reflecting the findings presented
 1159 above, these are likely to include age, gender, income, and education, as well as, almost
 1160 certainly, ethnicity. The difficulty arises when conducting international comparisons.
 1161

Benchmarking Access to Healthcare in the EU

1162 Other than age, gender, and education, few are consistently collected across countries.
1163 Moreover, the characteristics of interest may vary from one country to another. Thus,
1164 language or ethnicity may be of particular interest in one country but much less so in
1165 another. A further problem arises as some of the categories may be quite
1166 heterogeneous. Thus, some standard employment groupings may include people with
1167 quite different experiences. Ethnicity is particularly problematic. Thus, there may be
1168 considerable differences in the experiences of individuals from groups of neighbouring
1169 countries, as is the case with Indians, Pakistanis and Bangladeshis in the United
1170 Kingdom. Certain statistical problems may arise if the relative size of the categories
1171 varies greatly. Thus, where two categories of people form the top and bottom 2% of the
1172 distribution in a population, the distance between them will inevitably be much wider
1173 than in a country where they form the top and bottom 20%. A further problem relates to
1174 the issue of intersectionality, or the interaction between variables such as gender and
1175 ethnicity or religion (Bauer 2014).

1176 There are number of approaches in the literature measuring inequalities in health and
1177 healthcare utilisation (Wagstaff and Van Doorslaer 2000) that can be usefully adapted to
1178 the context of unmet need. To measure absolute inequalities within each country and
1179 compare across countries an approach based on the Lorenz curve could be used, plotting
1180 unmet need (ranked in increasing order) against the cumulative proportion of unmet
1181 need. This approach has been used for example to measure health inequalities (as
1182 measured by mortality or self-reported health). A regression-based approach could be
1183 used to decompose the inequalities as a function of different determinants.

1184 An alternative approach is to measure inequalities in unmet need along a specific
1185 dimension (e.g., socioeconomic status). An approach based on the concentration curve
1186 could be employed, which plots socio-economic status in increasing order against the
1187 cumulative proportion of unmet need. A curve above the diagonal would suggest that
1188 individuals with low socio-economic status have a higher share of unmet need. A
1189 regression-based approach could be used to measure and test for the presence of socio-

Benchmarking Access to Healthcare in the EU


1190 economic inequalities in unmet need. In its simplest formulation, this would involve
1191 regressing unmet need against socioeconomic status either for each country or for all
1192 countries (interacting socioeconomic status with country dummies). This regression
1193 approach would also give the option of taking account of certain variables (e.g., age and
1194 gender), providing a measure of socio-economic inequalities in unmet need which
1195 controls for populations characteristics. In contrast to the evidence on socio-economic
1196 inequalities in utilisation, it is not necessary to control for need (most often proxied by
1197 self-reported health) since this is already encompassed in the concept of unmet need
1198 (though the approach only holds if different individuals within and across countries
1199 perceive unmet need in the same way, which may not necessarily be the case). If unmet
1200 need is perceived differently, the inclusion of objective measure of need, e.g. morbidity
1201 or mortality may alleviate the problem but may suffer from reverse causality bias with
1202 unmet need affecting mortality and morbidity. The regression approach requires a more
1203 sophisticated analysis than is required if only collecting statistics and making them
1204 available. An unresolved issue is who will be responsible for producing such regression
1205 analysis.

1206 The evidence has generally focused on inequalities (differences) or inequities
1207 (differences that are unfair) in either health or utilisation (health care). The focus on
1208 unmet need is different since it blends both aspects of health, with poorer health
1209 increasing unmet need, and utilisation, with better access to healthcare reducing unmet
1210 need. The distinction between fair and unfair inequalities however remains. For example,
1211 countries differ in the public-private insurance mix, with some countries having
1212 duplicative private health insurance (e.g. in Italy, Spain and the UK) with patients with
1213 private health insurance being able to get treatment after shorter waits and able to
1214 choose their doctor. Some might argue that differences in unmet need by socioeconomic
1215 status due to richer individuals holding voluntary private health insurance is not
1216 considered unfair, even while agreeing that differences in unmet need by socioeconomic
1217 status within a National Health Service is unfair.

Benchmarking Access to Healthcare in the EU

1218 We suggest that these approaches are explored in future work. Meanwhile, descriptive
 1219 statistics of unmet need as experienced by certain groups, whose characteristics should
 1220 be subject to political discussion, can be reported for a range of dimensions and for each
 1221 Member State (so that for each dimension Member States can be compared along key
 1222 dimensions of inequalities). The scale of inequalities is illustrated in Figure 3-11, which
 1223 takes one of the simplest analyses, disaggregating individuals by income quintile.

1224 **Figure 3-13 Percentage of respondents reporting unmet need due to care being too**
 1225 **expensive, too far to travel, or long waiting list, by income quintile (2015)**
 1226



1227

1228 Note: In each case the poorest income quintile is the highest value and the richest is the
 1229 lowest

1230 Source: calculated from EU-SILC data

1231 It should also be noted that inequalities may be higher in countries where unmet need is
 1232 higher, and may reduce when the overall level of unmet need is reduced. An alternative
 1233 indicator is to produce simple inequality indices which standardise for the level of unmet
 1234 need (e.g. the coefficient of variation).

1235 **3.11. Proposals for additional data collection**

1236 The EU-SILC data have many strengths, especially that they already exist and have done
1237 for over a decade, providing a meaningful baseline against which to assess future
1238 developments. However, as described previously, they also have many weaknesses,
1239 including their restricted coverage, especially of some groups who are most vulnerable to
1240 unmet need, and their relatively few variables that can shed light on the nature and
1241 reasons for unmet need. Consequently, we consider it necessary to make proposals for
1242 investment in additional data sources that can inform policy and practice in the future.
1243 These fall into three categories. The first include those resources that already exist in
1244 one or more Member States but could, with additional resources, be extended to all.
1245 Among them is the Survey of Health, Ageing and Retirement in Europe (SHARE). This
1246 collects detailed data on many aspects of the lives of participants aged 50 and over in
1247 several Member States and has been an invaluable resource for understanding the
1248 health needs of ageing populations. As an example, SHARE data from France and Ireland
1249 were used to compare the extent to which formal and informal care substituted for each
1250 other (Gannon and Davin 2010).

1251 The second include those that are already in place in all Member States but which could
1252 be strengthened. The most obvious example is the EU-SILC, which contains few
1253 questions related to health need. While recognising the constraints imposed by
1254 participant fatigue, we propose a review of the variables currently collected to identify a
1255 small number of additional variables that could inform the quest to reduce unmet need.
1256 In particular, it will be important to improve the availability of data on mental health,
1257 and on unmet need for care of those with mental disorders. Another priority is to
1258 enhance mechanisms for collecting data on the most marginalised populations, groups
1259 whose characteristics will differ among countries, but who are often excluded from
1260 surveys, including, as already noted, the EU-SILC.

1261 The third category includes resources that do not currently exist or do so only in an *ad*
1262 *hoc* form. These might include the regular use of studies of so-called tracer conditions,
1263 for which the experience of patients captures the many potential barriers to accessing

1264 and achieving continuity of care. This has previously been applied mainly in middle
1265 income countries, using conditions such as diabetes (Balabanova, McKee et al. 2009,
1266 Kuhlbrandt, Balabanova et al. 2014) and hypertension (Risso-Gill, Balabanova et al.
1267 2015), but could be adapted to use in European countries.

1268 **3.12. Policies to reduce unmet need**

1269 Logically, these policies should follow the framework already set out, in that they should
1270 address affordability, availability, and user experience. This would suggest that we
1271 review briefly the evidence on out-of-pocket payments and unmet need.

1272 **3.12.1. Affordability**

1273 The Expert Panel's previous report noted the existence of variation in the benefits
1274 package in different Member States. It seems likely that these differences could
1275 contribute to differences in unmet need, for example where a particular service is
1276 excluded from the benefit package.

1277 That report also looked at user charges, noting how these also varied among Member
1278 States. There were three reasons for applying user charges. The first is to limit access to
1279 health care as a means to contain public spending on health, even though this may
1280 transfer costs to the individual. Second, to direct patients towards more cost-effective
1281 services. And third, to raise revenue for the health system. As was noted, there was little
1282 evidence to support any of these and the lack of a strong evidence base for user charges
1283 was noted. It seems reasonable to argue, on the basis of the available evidence, that
1284 user charges should, wherever possible, be eliminated for several reasons. First, they
1285 often cost as much to collect as they raise in revenue. Second, they are often highly
1286 regressive, and measures to reduce this, such as exemptions, create significant
1287 complications in operating the system. Third, they do not differentiate between
1288 necessary and unnecessary care in deterrent effect. There is, however, one possible
1289 exception. This is that they could be used to influence behaviour where the patient is
1290 faced with a choice as to how or where to obtain care. Thus, a charge may sometimes be
1291 appropriate to deter patients from buying unnecessary drugs or encourage patients to

Benchmarking Access to Healthcare in the EU

1292 attend primary care facilities rather than direct attendance at specialist facilities.
1293 However, even here, it is important to look at the reasons why patients go to a less
1294 appropriate setting, which may reflect geographical, temporal, or other barriers to
1295 accessing primary care. A related, but more difficult issue is that of informal payments,
1296 as noted above. These are widespread in some of the new Member States. They have
1297 been understood as a means of informal exit from the health system, or “inexit” (Gaal
1298 and McKee 2004). This follows from the work of Hirschman, who argued that
1299 discontented users normally have two options, except and voice (Hirschman 1970).
1300 However, under communism these systems offered neither, requiring a third option. The
1301 report noted that the most promising means of eliminating them was to take a
1302 comprehensive approach, involving adequate funding for the health system and greatly
1303 strengthen governance.

1304 **3.12.2.Availability & Accessibility**

1305 While noting the complexity involved in measuring access to health facilities, set out
1306 above, policies to improve it are likely to involve ensuring that the distribution of
1307 facilities matches that population. However, this poses a problem, because of the
1308 existence of economies of scale and scope. Thus, all health facilities require a critical
1309 mass and baseline level of activity to be viable, both in financial terms and in
1310 maintaining the expertise of those who work in them. The size of the critical mass will
1311 increase with the degree of complexity treatment being provided. In other words, there
1312 is often a trade-off in places where the population density is low. There are a number of
1313 imaginative solutions that can overcome this, many in use within the EU. They include
1314 the use of remote technologies, such as telemedicine (Saliba, Legido-Quigley et al.
1315 2012), and of shared use of facilities across national borders (Legido-Quigley, Glinos et
1316 al. 2012). Thus, it is important to ensure that any surveys recognise that the nearest
1317 facility may be in a neighbouring country, although clearly this is only of relevance if
1318 patients are able to cross the border to use it. There may, in some cases, be specific
1319 factors to consider, such as cross-border sharing of obstetric facilities, which can work

1320 well in some settings (Kiasuwa Mbengi, Baeten et al. 2014), but may create problems
1321 where the Member State in which a child is born may have implications for his or her
1322 nationality.

1323 **3.12.3. User experience**

1324 Although discussion of the measurement of user experience focused on waiting times/
1325 lists, as noted above, responsiveness involves many other dimensions. Thus, for a
1326 service to use, it will be necessary to pay attention to all of them.

1327 **3.13. Scope for action**

1328 In the report of the Expert Panel on Effective Ways of Investing in Health on "Access to
1329 Health Services in the European Union", actions to ensure equitable access were
1330 reviewed, summarizing national and EU-policy responses (Expert Panel on effective ways
1331 of investing in Health 2016).

1332 The report dealt with 8 dimensions, summarised below. The bullet points, which are
1333 based on the evidence in the earlier report and that reviewed previously in this one, are
1334 addressed to national and sub-national authorities, the precise nature of which will vary
1335 according to the institutional architecture of the health system in question. In each case
1336 we also make tentative suggestions about where there may be scope for European Union
1337 action to contribute added value, while stressing that each of these suggestions required
1338 much more detailed discussion than is possible here. In most cases, the rationale for
1339 including them was set out in the previous report.

1340 **Financial resources are linked to health need.**

- 1341 • countries with low levels of public spending on health should allocate a higher
1342 share of the government budget to the health sector;
- 1343 • the availability of public funding for health should be linked to population health
1344 needs, especially during economic down-turns;
- 1345 • public funding should be used for services that are evidence-based;

Benchmarking Access to Healthcare in the EU

- 1346 • sub-national resource allocation formulas should be reviewed regularly to ensure
1347 that they keep pace with changing situations;
- 1348 • provider payment that links payment solely to inputs is undesirable.

1349 The European Union already supports exchange of best practice in many areas, including
1350 data collection, helping countries to develop secure and confidential systems of record
1351 linkage and development of the expertise to make maximum use of the information so
1352 provided. These existing activities offer potential for further development.

1353 **Services are affordable for everyone.**

- 1354 • ensure most health system funding comes from public rather than private
1355 sources, identifying gaps in publicly financed coverage of cost-effective services;
- 1356 • keep out-of-pocket payments as low as possible;
- 1357 • encourage broadening of the basis for entitlement, where there are obvious gaps;
- 1358 • move away from discriminatory approaches such as entitlement linked to
1359 employment status or payment of contribution or situations in which people with
1360 different diagnoses are entitled to different benefits (inequity by disease);
- 1361 • review user charges to ensure that they do not create financial barriers to cost-
1362 effective services or undermine financial protection;
- 1363 • as fiscal and social protection policies are critical to address poverty and income
1364 inequality, encourage intersectoral cooperation and integrated health, social,
1365 education and employment services.

1366 The European Union could expand the scope of the EU-SILC data to include proxy
1367 measures of financial protection and could provide methodological support, in particular
1368 to develop comparable standards, for health-related aspects of household budget
1369 surveys. Ideally, these would be extended to look specifically at protection against the
1370 risk of catastrophic expenditure.

1371 **Services are relevant, appropriate and cost-effective.**

Benchmarking Access to Healthcare in the EU

- 1372 • ensure the publicly financed benefits package covers the full spectrum of
1373 services, and is correlated with population health needs and does not result in
1374 inequity by disease;
- 1375 • take steps to avoid over-medicalisation;
- 1376 • support the development of evidence-informed public health policies, including
1377 health promotion and disease prevention approaches, interventions and
1378 monitoring;
- 1379 • put in place systematic priority-setting processes to enable hta-informed, cost-
1380 effective coverage decisions for both new and existing technologies;
- 1381 • develop clinical guidelines and referral systems, adapt guidelines to meet the
1382 needs of people with multiple morbidities and monitor adherence to guidelines;
- 1383 • establish information systems to identify (and publicly report on) practice
1384 variations and patient outcomes and to support effective decision making by
1385 health professionals and patients;
- 1386 • develop and implement innovative payment systems that optimise the
1387 effectiveness and efficiency of health systems.

1388 The European Union has already done much to promote these actions, especially through
1389 the Horizon 2020 research programme and its predecessors, but also through initiatives
1390 in areas such as information technology and those carried out by projects such as
1391 EUnetHTA. All of these offer scope for further development.

1392 **Facilities are within easy reach.**

- 1393 • create administrative structures that can take a population-wide perspective and
1394 that have the managerial tools required for capacity planning;.
- 1395 • engage in area-level planning to create networks of dispersed facilities feeding
1396 into central ones, based on agreed clinical pathways;

Benchmarking Access to Healthcare in the EU

- 1397 • develop mechanisms to facilitate the transport of patients to health facilities or
1398 health professionals to patients.

1399 The European Union has already done much to improve access, through its structural
1400 funds, arrangements for cross-border care (especially as border areas often have low
1401 population densities) and European Reference Networks. All of these initiatives offer
1402 further potential.

1403 **There are enough health workers, with the right skills, in the right place.**

- 1404 • put in place processes to train adequate numbers of health workers with the
1405 necessary skills to meet population needs;
- 1406 • ensure an appropriate mix of skills is in place, taking account of the national
1407 context. this may require investment in additional administrative or care staff to
1408 relieve pressure on specialised health professionals, the development of specialist
1409 nurses, or task shifting, and competency-sharing with delegation of certain roles
1410 to less specialised staff where this can be clearly shown to be beneficial to
1411 patients;
- 1412 • establish working conditions designed to retain staff in underserved countries and
1413 areas: remuneration commensurate with skills and attention to broader working
1414 conditions, including access to peer support and continuing professional
1415 development.

1416 The European Union could support improvements on the collection of data on health
1417 worker functions, remuneration and working conditions. It could promote ethical
1418 practices in international recruitment in line with the WHO Global Code of Practice on the
1419 International Recruitment of Health Personnel.

1420 **Quality drugs and devices are readily available.**

- 1421 • Member States can benefit from common strategies to enhance access to
1422 medicine and devices;

Benchmarking Access to Healthcare in the EU

- 1423 • instruments are available, or should be made available, to improve negotiations
1424 between public payers and innovators for new medicines;
- 1425 • dialogue between member states and stakeholders should explore ways to reward
1426 R&D investment fairly but efficiently;
- 1427 • creating greater transparency about the costs of pharmaceutical products and the
1428 price of medicines would provide better grounds for assessing affordability,
1429 equitable access, fairness in pricing and incentives to develop new medicines;
- 1430 • strengthening access to off-patent and new medicines requires a comprehensive
1431 approach;
- 1432 • improve information systems and data collection at regional, national and EU
1433 level.

1434 The European Union could support existing initiatives to support improved approaches to
1435 procurement of medicines, based on transparency of prices. This will be a priority of the
1436 forthcoming Austrian Presidency. It could also encourage cooperation between Member
1437 States in the development of e-health solutions and information exchange between
1438 authorities and agencies across Member States.

1439 **People can use services when they need them.**

- 1440 • There is a need to enhance the evidence base for strategies to improve health
1441 literacy and empower service users;
- 1442 • it should be ensured that people have access good information about health
1443 services in their own language and have access to translation or interpretation
1444 services when required;
- 1445 • culturally sensitive and appropriate services should be strengthened (cultural
1446 competence);
- 1447 • Specify and adhere to maximum waiting times; differentiate waiting times by
1448 severity of illness;

Benchmarking Access to Healthcare in the EU

- 1449 • Individual health facilities can and should take a wide range of relatively
1450 straightforward steps to make existing services more easily accessible to the
1451 general population and to meet the needs of people with physical and intellectual
1452 disabilities.

1453 The European Union could support efforts to harmonise definition and data collection for
1454 waiting list/time indicators. It could also contribute to set and enforce standards for
1455 disabled access in all facilities, including those delivering healthcare.

1456 **Services are acceptable to everyone.**

- 1457 • Improve the communications skills of health workers, including transcultural
1458 aspects;
- 1459 • conduct regular national surveys of user experience of the health system,
1460 following good practices in countries such as Denmark, Spain, Sweden and the
1461 United Kingdom.

1462 **3.14. Proposals for qualitative measures**

1463 Given the complexity of unmet need for health care and its many causes, the indicators
1464 discussed above can never be more than that, simply indicators. Even the secondary
1465 indicators will only go so far in explaining differences in unmet need. It will be necessary
1466 to supplement these measures with additional information, in order to be able to assess
1467 the indicators appropriately and, potentially, to move from indicators to policy action.
1468 Such information must take account of the particular national context. Thus, unmet need
1469 due to distance from facilities should be understood differently, and reacted to
1470 differently, in, for example, Luxembourg, than in Northern Sweden.

1471 We propose development of a self-assessment tool, based on the concepts of
1472 affordability, availability, accessibility, and user experience as used above. Such a tool
1473 would need to be designed in a way that captured policy relevant inequalities within each
1474 country, the structure and operation of health systems, and other national specificities.
1475 These may influence the operationalisation of items like 'user experience', affordability,

Benchmarking Access to Healthcare in the EU

1476 inequality and the population included. An example is the definition of 'necessity of
1477 treatment' in the Netherlands, which is used in prioritisation of interventions for funding
1478 (Rappange and Brouwer 2012).

1479 Importantly, we do not advocate the adoption of a standard approach for use
1480 everywhere, because the issues to be addressed vary. Thus, while research by Eurostat
1481 using EU-SILC data, has demonstrated some general patterns in the correlates of unmet
1482 need across Europe, such as greater unmet need by those with lower incomes, who are
1483 older, or who have less education, there are also quite a number of exceptions (Eurostat
1484 2017). For example, reported unmet need is actually lower among older people in France
1485 and Sweden.

1486 Importantly, there are many groups who are not identified separately in EU-SILC data
1487 who are known, from other research, to be especially disadvantaged in obtaining access
1488 to care. These include certain ethnic or religious minorities, or those living in certain
1489 remote areas. It is, however, essential to recognise the complexity of the situation.
1490 Thus, while some ethnic minorities may be disadvantaged, others may not be, depending
1491 on factors arising from the characteristics of the minority concerned, including their
1492 degree of assimilation, their pattern of educational and employment status, their
1493 language ability, and the presence or absence of cultural barriers, as well as factors
1494 related to the provision of health services, including the scale and nature of
1495 discrimination and the availability of culturally appropriate services (Rechel, Mladovsky
1496 et al. 2013).

1497 The development of such a tool would involve : (i) defining access and its constituent
1498 elements, (ii) setting standards for its measurement, setting objectives for achievement
1499 in access to health care, (iii) interpreting data on access, (iv) qualitative research on
1500 access and (v) developing policy recommendations to improve access in general or for
1501 specific groups. We envisage that the approach would be iterative, starting from data on
1502 levels and determinants of unmet need from EU-SILC data, but also from research
1503 undertaken in the Member State concerned. Member States must thus determine

Benchmarking Access to Healthcare in the EU

1504 whether the dominant concerns relate to access in general or for particular groups or to
1505 certain services. These will vary, geographically and over time.

1506 Monitoring access to health care in itself is of limited value if not accompanied by the
1507 development of responses that are evaluated, and a willingness to act upon the findings.

1508 Hence, for the qualitative framework, we urge national governments to perform a self-
1509 assessment. A possible outline is as follows:

1510 a) a preamble with a statement on general policy goals in relation to (access to)
1511 health care;

1512 b) a summary of those groups that are likely to be disadvantaged. This should be
1513 based on a systematic analysis of characteristics that may give rise to
1514 disadvantage. A possible list, although not exhaustive, would include age, gender,
1515 education, income, disability, health status (especially the presence of mental
1516 illness), geographic location, homelessness, ethnicity, and religion. It should also
1517 consider intersectional issues, such as where being female and of a particular
1518 religion may be especially disadvantageous.

1519 c) Overview of the rights (both in terms of entitlements and effective execution of
1520 rights) of access to healthcare according to occupation/employment status. This
1521 analysis should include groups that are stigmatised, such as sex workers, and
1522 those in informal employment who are especially vulnerable. A particular
1523 emphasis should be placed on self-employed people and those in non-standard
1524 forms of work, taking account of the multiplicity of new types of contracts (in
1525 particular: casual work, involuntary part-time work, platform work, domestic
1526 workers, temporary agency workers). The analysis could integrate EU SILC data
1527 on unmet needs for self-employed people (in 2015, of those self-employed 55%
1528 were more likely to experience unmet needs than employees) as far as non-
1529 standard forms of work are concerned, it should look at legislative solutions in
1530 place and conditions for effective execution of rights to healthcare (identifying

Benchmarking Access to Healthcare in the EU

1531 possible barriers resulting from contractual conditions, non-compulsory insurance
1532 schemes, non-adherence to insurance due to affordability or financial hardship,
1533 etc).

1534 d) a review of data, from EU-SILC and national surveys, including those targeted at
1535 particular groups, of published literature on access to care, and from other
1536 sources, including reports by civil society groups. We encourage the use of ad hoc
1537 studies to understand the barriers experienced by particular groups. These could
1538 draw on More detailed analyses could draw on previous research using tracer
1539 conditions, as mentioned above, that seek to capture the barriers facing patients
1540 as they seek to access and achieve continuity of care (Balabanova, McKee et al.
1541 2009, Kuhlbrandt, Balabanova et al. 2014, Risso-Gill, Balabanova et al. 2015).

1542 e) an analysis of gaps in the available knowledge and an agenda for research.

1543 f) Proposals for actions to address the problems identified. These could usefully be
1544 formulated according to a standard set of headings (Box 3-5).

1545

1546 **Box 3-5 Checklist for measures to address unmet need**

1. Specify the main reasons for and expectations from the policy intervention. (Explain the reason for particular design and potential evidence for its effectiveness)
2. Which element(s) of access is the policy aiming to improve and how? (Explain the mechanism)
3. For which group(s) in society will the policy improve access? Will this decrease inequalities in access and/or health?
4. What is the expected (health) benefit of the particular intervention?
5. What are the expected costs of the intervention and who will pay these? (Note that besides financial costs this may also include reduced access or health in other areas or groups)
6. What are the main risks of the proposed policy?
7. Are the relevant (patient) groups involved in design of the policy?
8. How and by whom will the results of the policy be evaluated?

1547

1548 While we recommend that this self-assessment be undertaken by governments, we also
1549 encourage separate the shadow reports, such as those on the United Nations Convention
1550 on the Rights of the Child undertaken by non-governmental organisations (Hamm 2001).

1551 Finally, although we envisage that the self-assessment reports will be of most value to
1552 the countries themselves, we believe that there is considerable scope for shared
1553 learning, in particular from those countries that have been most successful in reducing
1554 levels of unmet need over time, with a particular focus on policy responses that have
1555 managed to improve access and reduce unmet need for systematically underserved
1556 population groups. For this reason, it is desirable that the reports be published and easily
1557 available. To the extent possible, they should be reported in a standardised format that
1558 would make it easy to undertake comparative analysis.

1559 **3.15. Scope for utilization of EU funds and/or other mechanisms to** 1560 **support the improvement of access to healthcare according to the** 1561 **benchmarks proposed.**

1562 First, as the problems facing each Member State will differ, as will the solutions, it will be
1563 necessary for policies to be designed, developed and implemented at the level of the
1564 Member State, ideally based on the self-assessment set out above. In some cases, the
1565 responses might be able to exploit existing EU funding mechanisms, such as structural
1566 funds or low cost loans from the European Investment Bank, where, in addition,
1567 supporting investment environment under the Investment Plan for Europe is available
1568 through the European Investment Advisory Hub (European Investment Bank 2017) and
1569 the EU Investment Project Portal (European Commission 2017).

1570 European Structural and Investment Funds (ESIF) are the main mechanism for obtaining
1571 funds to invest in healthcare, offering support for the EU Cohesion Policy seeking to
1572 reduce economic and social disparities between regions in Europe. Health, as an
1573 important contributor to regional development and competitiveness, is supported by the
1574 European Regional Development Fund (ERDF) and European Social Fund. Health
1575 investments by the ESIF must form part of a coherent policy strategy, based on a needs
1576 assessment, and should demonstrate cost-effectiveness (European Commission 2014).
1577 Thus, ongoing investments in infrastructure are included within larger health investment
1578 policies including: (i) deinstitutionalization and development of community-based care,
1579 (ii) promotion of active and healthy ageing, (iii) improving access to and quality of health
1580 care services, (iv) health promotion and disease prevention, (v) continued education of
1581 medical staff and (vi) increased efforts in the field of e-health (European Commission
1582 2016). Nevertheless, there is much scope to improve access to high quality health care
1583 through upgrading existing healthcare infrastructure, although this should take an
1584 integrated investment approach: infrastructure, technology and service models should
1585 be considered together – an “investment triangle in health” (European Commission
1586 2017).

Benchmarking Access to Healthcare in the EU

1587 Technical assistance available through the Structural Reform Support Service provides
1588 assistance for EU countries to design and carry out structural reforms as part of their
1589 efforts to support job creation and sustainable growth. At their individual request,
1590 Member States can receive funding to design reforms to increase access to healthcare,
1591 with self-assessment of needs and challenges being an integral part of such projects.

1592 There are also some Europe wide initiatives that offer potential to reduce unmet need for
1593 healthcare. The following list is not exhaustive, but does give some idea of the scope of
1594 activities underway and their future potential.

1595 **Support for better information**

1596 The European Research Infrastructure Consortium on Health Information for Research
1597 and Evidence-based Policy has identified significant weaknesses in health information
1598 (infra)structures in Europe (HIREP-ERIC 2017). This is something that could be
1599 addressed using structural funds. A proposed area that could be developed would be to
1600 support evaluation of methods to use administrative data already routinely collected for
1601 central purposes according to unified national methodologies (i.e. for national statistics,
1602 health insurance) to produce benchmarks for access to healthcare. Administrative data
1603 are relatively inexpensive, readily available, and already used for hospital quality
1604 improvement / quality benchmarks. In the USA the Agency for Healthcare Research and
1605 Quality has shown what can be done with investment in development and refinement of
1606 administrative data to generate indicators for use in quality improvement and national
1607 tracking (Agency for Healthcare Research and Quality 2017). There are other examples
1608 of how such data can be used to produce quality measures (Iezzoni 1997, Weingart,
1609 Iezzoni et al. 2000, Department of Health 2002).

1610 Throughout this report, the limitations of available data have been noted. There are,
1611 however, a number of data sources that could, with limited investment, make a greater
1612 contribution. One is the Survey of Health, Ageing, and Retirement in Europe, which
1613 collects extensive data on those aged 50 and over in 27 European countries and Israel.
1614 There is a strong case for reviewing how it might be used and, if necessary, augmented

1615 to yield more detailed information on unmet need for health care, and its determinants,
1616 in Europe.

1617 **Support for exchange of best practice**

1618 The Research Area network (ERA-NET), funded by Horizon 2020, offers a tool to support
1619 exchange of good practices among Member States. The European Innovation
1620 Partnership on Active and Healthy Ageing has established a repository of innovative
1621 practices, many of which can contribute to reducing barriers faced by older people. The
1622 Patient Access Partnership (PACT) has developed a framework for improving access to
1623 health care within and between European countries. This framework includes: (a) the
1624 '5As' definition of access, which details the five critical elements (adequacy, accessibility,
1625 affordability, appropriateness, and availability) of access to health care, (b) a multi-
1626 stakeholder approach to mapping access, and (c) a 13-item questionnaire based on the
1627 5As definition (Souliotis, Hasardzhiev et al. 2016). More generally, the European Patient
1628 Forum suggests that more research is needed to define indicators of access and health
1629 system performance, using EU funds from sources such as the public health programme
1630 and Horizon 2020. They argue that patient organisations should be involved
1631 meaningfully in these projects, according to existing good practices/recommendations
1632 (European Patient Forum 2016).

1633 **European Reference networks**

1634 European Reference Networks now link over 300 hospitals in 26 Member States, offering
1635 access to highly specialised care for complex or rare diseases and conditions (European
1636 Commission 2017). While benefiting only small numbers of patients, relatively, they
1637 represent a concrete manifestation of what the European Union can do that is beyond
1638 the capacity of any individual Member State. However, while EU funding supports the
1639 operation of the networks, there are concerns that their benefits may not be available
1640 equally to all Europeans, especially those in poorer Member States. Consequently, there
1641 is a case for examining whether EU funding might be able to address this.

1642 **3.16. Conclusion**

1643 The principles and rights enshrined in the European Pillar of Social Rights, including
1644 access to healthcare, fall under the competence of the EU, the Member States and social
1645 partners. Being a joint endeavour, the pillar sets the framework to improve social
1646 standards in Europe, but the centre of gravity remains with national and local
1647 authorities. This opinion provides guidance and a tool which could be used by Member
1648 States to progress on closing their gaps in access to healthcare. It sets a practical
1649 framework to lead the way forward for better understanding, identifying, and addressing
1650 the gaps in access to healthcare.

1651 The extent to which Europe's citizens experience unmet need for health care varies
1652 enormously. While it now appears that increases in several countries, coinciding with
1653 austerity policies, may now be reversing, there can be no grounds for complacency.
1654 There is now high level political commitment to address this issue but, to do so, it is
1655 essential to put in place systems to quantify the scale of the problem and monitor the
1656 impact of policies.

1657 In practical terms, there is only one source of data collected in all Member States in a
1658 reasonably consistent way. This is the EU-SILC which, fortunately, has been collected for
1659 a number of years, making it possible to define a baseline. However, it is in many
1660 respects quite limited. Sample sizes are low, only a few questions on unmet need are
1661 included, and the samples do not capture the entire population, with some important
1662 exclusions of vulnerable groups. Nonetheless, pending any future improvements, we
1663 recommend that it be used as a basic means of monitoring unmet need. We also propose
1664 a mechanism to set goals for progress in reducing unmet need that recognise the
1665 different starting points of Member States but which are both challenging and
1666 achievable. However, we note that selection of the precise targets is a political rather
1667 than a technical process. We believe that it should be possible to agree and implement
1668 such targets within 1-2 years.

Benchmarking Access to Healthcare in the EU

1669 While it is essential to have information on overall levels of unmet need, it is as
1670 important to be able to explain them. The EU-SILC data provide some insights, with
1671 questions on affordability, availability, and acceptability. However, appropriate policy
1672 changes require much more information. Consequently, we recommend that Member
1673 States undertake qualitative assessments of unmet need, taking account the specific
1674 issues they face and the groups and services that are most affected. We do not propose
1675 a blueprint for doing this; rather we argue for responsible authorities to explore, with the
1676 research community, the most appropriate design for the questions they are asking.
1677 However, we do recommend that these assessments should be published and should be
1678 subject to consultation with the public.

1679 We also make a number of suggestions for policies to reduce unmet need. We do not go
1680 into detail with them as they were covered in detail in our previous report. However, we
1681 do identify a number of European initiatives that can facilitate exchange of good practice
1682 and investment in areas that can help reduce unmet need.

1683 Although not addressed in detail here, it is apparent that there is a great need for further
1684 research on unmet need and its determinants in Europe. This should include studies that
1685 help to understand how need for healthcare is perceived among and within Member
1686 States, the practical barriers that different groups face, and the effectiveness of
1687 interventions to overcome these barriers.

1688 Finally, if our recommendations are accepted and implemented, it can be expected that
1689 the scale and nature of unmet need in Member States will be much better understood.
1690 Consequently, we recommend that this issue is revisited in 3-5 years.

1691

1692

1693 **4. LIST OF ABBREVIATIONS**

1694	ERA-NET	European Research Area Network
1695	ERDF	European Regional Development Fund
1696	HIREP-ERIC	European Research Infrastructure Consortium on Health Information for
1697		Research and Evidence-based Policy
1698	ESIF	European Structural and Investment Funds
1699	EU	European Union
1700	EU-SILC	European Union Survey of Income and Living Conditions
1701	OECD	Organisation for Economic Co-operation and Development
1702	PACT	Patient Access Partnership
1703		
1704		

DRAFT

1705 5. REFERENCES

- 1706 Agency for Healthcare Research and Quality. (2017). "AHRQuality Indicators."
1707 Retrieved 3rd October, 2017, from <http://www.qualityindicators.ahrq.gov/>.
- 1708 Appleby, J., V. Raleigh, F. Frosini, G. Bevan, G. HaiYan and T. Lyscom (2011). Variations
1709 in health care: the good, the bad and the inexplicable. London, King's Fund.
- 1710 Arora, V. S., M. Karanikolos, A. Clair, A. Reeves, D. Stuckler and M. McKee (2015).
1711 "Data Resource Profile: The European Union Statistics on Income and Living Conditions
1712 (EU-SILC)." Int J Epidemiol **44**(2): 451-461.
- 1713 Arora, V. S., C. Kuhlbrandt and M. McKee (2016). "An examination of unmet health
1714 needs as perceived by Roma in Central and Eastern Europe." Eur J Public Health **26**(5):
1715 737-742.
- 1716 Arrow, K. J. (2001). "Uncertainty and the Welfare Economics of Medical Care (American
1717 Economic Review, 1963)." Journal of Health Politics, Policy and Law **26**(5): 851-883.
- 1718 Balabanova, D., M. McKee, N. Koroleva, I. Chikovani, K. Gogvadze, T. Kobaladze, O.
1719 Adeyi and S. Robles (2009). "Navigating the health system: diabetes care in Georgia."
1720 Health Policy Plan **24**(1): 46-54.
- 1721 Bauer, G. R. (2014). "Incorporating intersectionality theory into population health
1722 research methodology: Challenges and the potential to advance health equity." Social
1723 Science & Medicine **110**: 10-17.
- 1724 Black, N., M. Murphy, D. Lamping, M. McKee, C. Sanderson, J. Askham and T. Marteau
1725 (1999). "Consensus development methods: a review of best practice in creating clinical
1726 guidelines." J Health Serv Res Policy **4**(4): 236-248.
- 1727 Department of Health (2002). NHS performance indicators. London, Department of
1728 Health.
- 1729 Dixon, H. and L. Siciliani (2009). "Waiting-time targets in the healthcare sector: how
1730 long are we waiting?" J Health Econ **28**(6): 1081-1098.
- 1731 Doran, G. T. (1981). "There's a SMART way to write management's goals and
1732 objectives." Management Review **70**(11): 35-36.
- 1733 European Commission. (2014). "Policy Guide for Health Investments in European
1734 Structural and Investment Funds 2014-2020." Retrieved 13th June, 2017, from
1735 [http://ec.europa.eu/regional_policy/sources/docgener/informat/2014/thematic_guidance](http://ec.europa.eu/regional_policy/sources/docgener/informat/2014/thematic_guidance_fiche_health_investments.pdf)
1736 [fiche_health_investments.pdf](http://ec.europa.eu/regional_policy/sources/docgener/informat/2014/thematic_guidance_fiche_health_investments.pdf).
- 1737 European Commission. (2016). "Mapping of the use of European Structural and
1738 Investment Funds in the 2007-2013 and 2014-+2020 programming periods." Retrieved
1739 13th June, 2017, from http://www.esifforhealth.eu/pdf/Mapping_Report_Final.pdf.
- 1740 European Commission. (2017). "About European Reference Networks (ERNs)."
1741 Retrieved 13th June, 2017, from [http://www.eurordis.org/content/about-european-](http://www.eurordis.org/content/about-european-reference-networks)
1742 [reference-networks](http://www.eurordis.org/content/about-european-reference-networks).
- 1743 European Commission. (2017). "European Investment Project Portal (EIPP)." Retrieved
1744 14th June, 2017, from <https://ec.europa.eu/eipp/desktop/en/index.html>.
- 1745 European Commission. (2017). "European Pillar of Social Rights." Retrieved 24th June,
1746 2017, from [https://ec.europa.eu/commission/priorities/deeper-and-fairer-economic-and-](https://ec.europa.eu/commission/priorities/deeper-and-fairer-economic-and-monetary-union/european-pillar-social-rights_en)
1747 [monetary-union/european-pillar-social-rights_en](https://ec.europa.eu/commission/priorities/deeper-and-fairer-economic-and-monetary-union/european-pillar-social-rights_en).
- 1748 European Commission. (2017). "Seminar on"Strategic investments for the future of
1749 healthcare"." Retrieved 13th June, 2017, from
1750 [http://ec.europa.eu/health/sites/health/files/investment_plan/docs/ev_20170227_mi_en](http://ec.europa.eu/health/sites/health/files/investment_plan/docs/ev_20170227_mi_en.pdf)
1751 [.pdf](http://ec.europa.eu/health/sites/health/files/investment_plan/docs/ev_20170227_mi_en.pdf).
- 1752 European Investment Bank. (2017). "European Investment Advisory Hub." Retrieved
1753 14th June, 2017, from <http://www.eib.org/eiah/>.
- 1754 European Patient Forum. (2016). "Defining and Measuring Access to Healthcare: the
1755 Patients' Perspective." Retrieved 13th June, 2017, from [http://www.eu-](http://www.eu-patient.eu/globalassets/policy/access/epf_position_defining_and_measuring_access_010316.pdf)
1756 [patient.eu/globalassets/policy/access/epf_position_defining_and_measuring_access_010](http://www.eu-patient.eu/globalassets/policy/access/epf_position_defining_and_measuring_access_010316.pdf)
1757 [316.pdf](http://www.eu-patient.eu/globalassets/policy/access/epf_position_defining_and_measuring_access_010316.pdf).

Benchmarking Access to Healthcare in the EU

- 1758 Eurostat. (2017). "Unmet health care needs statistics." Retrieved 16th September,
1759 2017, from [http://ec.europa.eu/eurostat/statistics-](http://ec.europa.eu/eurostat/statistics-explained/index.php/Unmet_health_care_needs_statistics)
1760 [explained/index.php/Unmet_health_care_needs_statistics](http://ec.europa.eu/eurostat/statistics-explained/index.php/Unmet_health_care_needs_statistics).
- 1761 Expert Panel on effective ways of investing in Health (2016). Access to health services.
1762 Brussels, European Commission.
- 1763 Gaal, P., P. C. Belli, M. McKee and M. Szocska (2006). "Informal payments for health
1764 care: definitions, distinctions, and dilemmas." J Health Polit Policy Law **31**(2): 251-293.
- 1765 Gaal, P. and M. McKee (2004). "Informal payment for health care and the theory of
1766 'INXIT'." Int J Health Plann Manage **19**(2): 163-178.
- 1767 Gannon, B. and B. Davin (2010). "Use of formal and informal care services among older
1768 people in Ireland and France." Eur J Health Econ **11**(5): 499-511.
- 1769 GBD 2015 Healthcare Access and Quality Collaborators (2017). "Healthcare Access and
1770 Quality Index based on mortality from causes amenable to personal healthcare in 195
1771 countries and territories, 1990-2015: a novel analysis from the Global Burden of
1772 Disease 2015 study." Lancet **390**: 231-266.
- 1773 Gray, M., M. Airoidi, G. Bevan and P. McCulloch (2017). "Deriving optimal value from
1774 each system." J R Soc Med: doi: 10.1177/0141076817711090.
- 1775 Greer, S. L., T. K. Hervey, J. P. Mackenbach and M. McKee (2013). "Health law and
1776 policy in the European Union." The Lancet **381**(9872): 1135-1144.
- 1777 Hamm, B. I. (2001). "A human rights approach to development." Human Rights
1778 Quarterly **23**(4): 1005-1031.
- 1779 Hart, J. T. (1971). "The inverse care law." Lancet **297**(7696): 405-412.
- 1780 Hiam, L. and M. McKee (2016). "Making a fair contribution: is charging migrants for
1781 healthcare in line with NHS principles?" Journal of the Royal Society of Medicine **109**(6):
1782 226-229.
- 1783 HIREP-ERIC. (2017). "A research infrastructure to advance public health monitoring and
1784 research on health and care. Technical and scientific description." Retrieved 13th June,
1785 2017, from <http://www.bridge-health.eu/Meeting20April2017>.
- 1786 Hirschman, A. O. (1970). Exit, voice, and loyalty: Responses to decline in firms,
1787 organizations, and states. Cambridge, MA, Harvard University Press.
- 1788 Iezzoni, L. I. (1997). "Assessing quality using administrative data." Ann Intern Med
1789 **127**(8 Pt 2): 666-674.
- 1790 Jordan, H., P. Roderick, D. Martin and S. Barnett (2004). "Distance, rurality and the
1791 need for care: access to health services in South West England." International journal of
1792 health geographics **3**(1): 21.
- 1793 Juncker, J.-C., D. Tusk, J. Dijsselbloem, M. Draghi and M. Schulz (2015). Completing
1794 Europe's economic and monetary union. Brussels, European Commission.
- 1795 Kachalia, A., A. Berg, A. Fagerlin, K. E. Fowler, T. P. Hofer, S. A. Flanders and S. Saint
1796 (2015). "Overuse of testing in preoperative evaluation and syncope: a survey of
1797 hospitalists." Ann Intern Med **162**(2): 100-108.
- 1798 Karanikolos, M., V. S. Gordeev, J. P. Mackenbach and M. McKee (2016). "Access to care
1799 in the Baltic States: did crisis have an impact?" Eur J Public Health **26**(2): 236-241.
- 1800 Kentikelenis, A., M. Karanikolos, A. Reeves, M. McKee and D. Stuckler (2014). "Greece's
1801 health crisis: from austerity to denialism." Lancet **383**(9918): 748-753.
- 1802 Khatib, R., J. D. Schwalm, S. Yusuf, R. B. Haynes, M. McKee, M. Khan and R. Nieuwlaat
1803 (2014). "Patient and healthcare provider barriers to hypertension awareness, treatment
1804 and follow up: a systematic review and meta-analysis of qualitative and quantitative
1805 studies." PLoS One **9**(1): e84238.
- 1806 Kiasuwa Mbengi, R. L., R. Baeten, M. McKee and C. Knai (2014). "Issues arising when
1807 crossing a border to give birth: an exploratory study on the French-Belgian border."
1808 Facts Views Vis Obgyn **6**(3): 127-132.
- 1809 Kuhlbrandt, C., D. Balabanova, I. Chikovani, V. Petrosyan, K. Kizilova, O. Ivaniuto, O.
1810 Danii, N. Makarova and M. McKee (2014). "In search of patient-centred care in middle
1811 income countries: the experience of diabetes care in the former Soviet Union." Health
1812 Policy **118**(2): 193-200.

Benchmarking Access to Healthcare in the EU

- 1813 Kuhlbrandt, C., K. Footman, B. Rechel and M. McKee (2014). "An examination of Roma
1814 health insurance status in Central and Eastern Europe." Eur J Public Health **24**(5): 707-
1815 712.
- 1816 Legido-Quigley, H., I. A. Glinos, R. Baeten, M. McKee and R. Busse (2012). "Analysing
1817 arrangements for cross-border mobility of patients in the European Union: a proposal for
1818 a framework." Health Policy **108**(1): 27-36.
- 1819 Legido-Quigley, H., M. Karanikolos, S. Hernandez-Plaza, C. de Freitas, L. Bernardo, B.
1820 Padilla, R. Sa Machado, K. Diaz-Ordaz, D. Stuckler and M. McKee (2016). "Effects of the
1821 financial crisis and Troika austerity measures on health and health care access in
1822 Portugal." Health Policy **120**(7): 833-839.
- 1823 Legido-Quigley, H., E. Urdaneta, A. Gonzalez, D. La Parra, C. Muntaner, C. Alvarez-
1824 Dardet, J. M. Martin-Moreno and M. McKee (2013). "Erosion of universal health coverage
1825 in Spain." The Lancet **382**(9909): 1977.
- 1826 Maimaris, W., J. Paty, P. Perel, H. Legido-Quigley, D. Balabanova, R. Nieuwlaat and M.
1827 McKee (2013). "The influence of health systems on hypertension awareness, treatment,
1828 and control: a systematic literature review." PLoS Med **10**(7): e1001490.
- 1829 Marmot, M., S. Friel, R. Bell, T. A. Houweling, S. Taylor and C. o. S. D. o. Health (2008).
1830 "Closing the gap in a generation: health equity through action on the social determinants
1831 of health." The Lancet **372**(9650): 1661-1669.
- 1832 McCartney, M. (2013). The patient paradox. London, Pinter & Martin Publishers.
- 1833 McKee, C. M., D. N. Gleadhill and J. D. Watson (1990). "Accident and emergency
1834 attendance rates: variation among patients from different general practices." Br J Gen
1835 Pract **40**(333): 150-153.
- 1836 McKee, M. and J. Healy (2002). Hospitals in a changing Europe. Buckingham, Open
1837 University Press.
- 1838 McKee, M., E. Mossialos and P. Belcher (1996). "The influence of European law on
1839 national health policy." Journal of European Social Policy **6**(4): 263-286.
- 1840 McKee, M., J. M. Whatling, J. L. Wilson and A. Vallance-Owen (2005). "Comparing
1841 outcomes of cataract surgery: challenges and opportunities." J Public Health (Oxf)
1842 **27**(4): 348-352.
- 1843 Missinne, S., B. Meuleman and P. Bracke (2013). "The popular legitimacy of European
1844 healthcare systems: A multilevel analysis of 24 countries." Journal of European social
1845 policy **23**(3): 231-247.
- 1846 Nolte, E. and M. McKee (2011). "Variations in amenable mortality--trends in 16 high-
1847 income nations." Health Policy **103**(1): 47-52.
- 1848 Nuti, S. and M. Vainieri (2012). "Managing waiting times in diagnostic medical imaging."
1849 BMJ Open **2**(6).
- 1850 OECD (2016). Health at a Glance: Europe 2016. Paris, OECD.
- 1851 OECD, E. C. a. (2016). Health at a glance: Europe 2016. Paris, OECD.
- 1852 Purdy, S., T. Griffin, C. Salisbury and D. Sharp (2009). "Ambulatory care sensitive
1853 conditions: terminology and disease coding need to be more specific to aid policy makers
1854 and clinicians." Public health **123**(2): 169-173.
- 1855 Rappange, D. R. and W. B. Brouwer (2012). "The evaluation of lifestyle interventions in
1856 the Netherlands." Health Econ Policy Law **7**(2): 243-261.
- 1857 Rechel, B., P. Mladovsky, D. Ingleby, J. P. Mackenbach and M. McKee (2013). "Migration
1858 and health in an increasingly diverse Europe." The Lancet **381**(9873): 1235-1245.
- 1859 Reeves, A., M. McKee and D. Stuckler (2015). "The attack on universal health coverage
1860 in Europe: recession, austerity and unmet needs." Eur J Public Health **25**(3): 364-365.
- 1861 Risso-Gill, I., D. Balabanova, F. Majid, K. K. Ng, K. Yusoff, F. Mustapha, C. Kuhlbrandt,
1862 R. Nieuwlaat, J. D. Schwalm, T. McCreedy, K. K. Teo, S. Yusuf and M. McKee (2015).
1863 "Understanding the modifiable health systems barriers to hypertension management in
1864 Malaysia: a multi-method health systems appraisal approach." BMC Health Serv Res **15**:
1865 254.
- 1866 Saliba, V., H. Legido-Quigley, R. Hallik, A. Aaviksoo, J. Car and M. McKee (2012).
1867 "Telemedicine across borders: a systematic review of factors that hinder or support
1868 implementation." Int J Med Inform **81**(12): 793-809.

Benchmarking Access to Healthcare in the EU

- 1869 Sanderson, C. F., D. J. Hunter, C. M. McKee and N. A. Black (1997). "Limitations of
1870 epidemiologically based needs assessment. The case of prostatectomy." Med Care
1871 **35**(7): 669-685.
- 1872 Schreyogg, J., T. Stargardt, M. Velasco-Garrido and R. Busse (2005). "Defining the
1873 "Health Benefit Basket" in nine European countries. Evidence from the European Union
1874 Health BASKET Project." Eur J Health Econ Suppl: 2-10.
- 1875 Shahvisi, A. (2016). "No Understanding, No Consent: The Case Against Alternative
1876 Medicine." Bioethics **30**(2): 69-76.
- 1877 Siciliani, L., V. Moran and M. Borowitz (2014). "Measuring and comparing health care
1878 waiting times in OECD countries." Health Policy **118**(3): 292-303.
- 1879 Sizmur, S., C. Graham and J. Walsh (2015). "Influence of patients' age and sex and the
1880 mode of administration on results from the NHS Friends and Family Test of patient
1881 experience." J Health Serv Res Policy **20**(1): 5-10.
- 1882 Souliotis, K., S. Hasardzhiev and E. Agapidaki (2016). "A Conceptual Framework of
1883 Mapping Access to Health Care across EU Countries: The Patient Access Initiative." Public
1884 health genomics **19**(3): 153-159.
- 1885 Sridhar, D., M. McKee, G. Ooms, C. Beiersmann, E. Friedman, H. Gouda, P. Hill and A.
1886 Jahn (2015). "Universal Health Coverage and the Right to Health: From Legal Principle to
1887 Post-2015 Indicators." Int J Health Serv **45**(3): 495-506.
- 1888 Sridhar, D., M. McKee, G. Ooms, C. Beiersmann, E. Friedman, H. Gouda, P. Hill and A.
1889 Jahn (2015). "Universal health coverage and the right to health: from legal principle to
1890 post-2015 indicators." International journal of health services **45**(3): 495-506.
- 1891 Stevens, A. and S. Gillam (1998). "Needs assessment: from theory to practice." BMJ :
1892 British Medical Journal **316**(7142): 1448-1452.
- 1893 Suhrcke, M., M. McKee, J. Mortensen, R. S. Arce and S. Tsoleva (2005). The contribution
1894 of health to the economy in the European Union. Luxembourg, European Commission.
- 1895 UNDP. (2015). "Sustainable Development Goals." Retrieved 24th June, 2017, from
1896 <http://www.undp.org/content/undp/en/home/sustainable-development-goals.html>.
- 1897 United Nations. (1966). "International Covenant on Economic, Social and Cultural
1898 Rights." Retrieved 24th June, 2017, from
1899 <http://www.ohchr.org/EN/ProfessionalInterest/Pages/CESCR.aspx>.
- 1900 Wagstaff, A. and E. Van Doorslaer (2000). "Equity in health care finance and delivery."
1901 Handbook of health economics **1**: 1803-1862.
- 1902 Weingart, S. N., L. I. Iezzoni, R. B. Davis, R. H. Palmer, M. Cahalane, M. B. Hamel, K.
1903 Mukamal, R. S. Phillips, D. T. Davies, Jr. and N. J. Banks (2000). "Use of administrative
1904 data to find substandard care: validation of the complications screening program." Med
1905 Care **38**(8): 796-806.
- 1906 Wennberg, J. E. (1999). "Understanding geographic variations in health care delivery." N
1907 Engl J Med **340**(1): 52-53.
- 1908 Wilcock, G. K. (1979). "The prevalence of osteoarthritis of the hip requiring total hip
1909 replacement in the elderly." Int J Epidemiol **8**(3): 247-250.
- 1910 Wismar, M., M. McKee, K. Ernst, D. Srivastava and R. Busse (2008). Health targets in
1911 Europe: Learning from experience. Copenhagen, World Health Organization.
- 1912 World Health Organization (2000). The world health report 2000: health systems:
1913 improving performance. Geneva, World Health Organization.
- 1914 World Health Organization (2008). Summary of the evidence on patient safety:
1915 implications for research. Geneva, WHO.
- 1916 Xu, K. (2005). Distribution of health payments and catastrophic expenditures
1917 methodology. Geneva, World Health Organization.
- 1918